CONFIDENTIAL – FOIA Exemptions Apply in U.S. 1
Status: Approved, Date: 23 February 2021Janssen Research & Development*
Clinical Protocol
Protocol Title
Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart 
Failure
CHIEF-HF
Protocol 28431754HFA3002; Phase 3B
AMENDMENT 3
JNJ-28431754 (canagliflozin) (INVOKANA)
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Developmentstudies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen
Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout
the protocol to represent these various legal entities; the sponsor is identified on the Contact [CONTACT_97455].
US sites of this study will be conducted under US Food & Drug Administration IND regulations 
(21 CFR Part 312).
Status: Approved
Date: 23 February 2021
Prepared by: [CONTACT_263726]: EDMS-ERI-154820237, 6.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipi[INVESTIGATOR_70281], regulations, rules, protective orders or otherwise.[STUDY_ID_REMOVED]
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 2
Approved, Date: 23 February 2021PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 3 23 February 2021
Amendment 2 02 June 2020
Amendment 1 07 February 2020
Original Protocol 07 November 2019
Amendment 3 (23 February 2021)
Overall Rationale for the Amendment: The overall rationale for the amendment is to clarify the adverse 
event (AE) reporting requirements and time frames for the study.
Section number
and NameDescription of Change Brief Rationale
Synopsis (Adverse 
Event Data Collection, 
Adverse Event 
Evaluations, Adverse Event Analyses);
3. Objectives and
Endpoints (AdverseEvent Data
Collection);
8.3. Adverse Events
and Serious Adverse
Events and Special
Situations;8.3.1 . Time Period and
Frequency for
Collecting Adverse
Event and Serious
Adverse Event
Information;
9.4.3 Adverse Event
AnalysisThe following text was modified:
“Due to the virtual method of data collection for 
this study, there will be 2 types of adverse event 
data collection ,one will be done by [CONTACT_263727]-report any adverse events from 
the study intervention to a call center, and the 
other by [CONTACT_263728]’s provider to their insurance system. Participant-reported adverse events to 
the call center will be captured from the time 
of informed consent until 30 days after the end 
of treatment (ie, the last dose of study 
intervention) and adverse events from medical claims data from the time of informed consent 
to the end of study. Adverse events will be 
captured from the time of informed consent 
through the end of treatment (Month 3) plus 30 
days. After the treatment period plus 30 days, 
serious adverse events will be identified solely 
through medical claims data. Adverse events that occur during the treatment period plus 30 days identified from medical claims will be 
aggregated by [CONTACT_263729]. In addition, for this time period, self-reported adverse events from the call center will be summarized in a listing. Serious adverse event data from medical 
claims for the 9-month study period will be 
aggregated by [CONTACT_15500]. Medical 
claims adverse event data will be reviewed and 
evaluated in aggregate at the end of the 3 month, 
double blind treatment period when the 
unblinded data are available.”To clarify that 
1. Adverse events will be collected
from medical claims as well as
from the call center, from the timeof informed consent through the
end of treatment plus 30 days.
2. After the treatment period plus30 days, serious adverse events
will be identified from medical
claims data.
3. Aggregated adverse events from
medical claims data will be
presented for the treatment periodplus 30 days. In addition, for the
same period, a listing will be
provided for the self-reported
adverse events from the call
center.
4. Serious adverse events from
medical claims will besummarized at the end of the9-month study period.
1.3Schedule of 
Activities (SoA)Reporting of adverse events is extended from end 
of treatment to end of study in SoA table.
Footnote ‘e’ revised to ‘ Participant-reported 
adverse events to the call center occurs Lasts
from the time of informed consent until 30 days 
after the end of treatment (ie, the last dose of To clarify the duration of 
self-reported adverse events from
call center and adverse eventscollected from medical claim data.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 3
Approved, Date: 23 February 2021Section number
and NameDescription of Change Brief Rationale
study intervention). Adverse events from 
medical claims data occurs from the time of 
informed consent to the end of study. ’
10.1 Appendix 1: 
AbbreviationsAbbreviation list updated for an ‘SAE’. Minor errors were noted.
Throughout the 
protocolMinor formatting and consistency changes were 
made.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 4
Approved, Date: [ADDRESS_320794] OF IN-TEXT TABL ES AND FIGURES ............................................................................................. ...5
1. PROTOCOL SUMMARY ............................................................................................................. ........ 6
1.1. Synopsis................................................................................................................... ........................ 6
1.2. Schema ..................................................................................................................... ..................... 11
1.3. Schedule of Activities (SoA)............................................................................................... ............ 12
2. INTRODUCTION................................................................................................................. ............... 14
2.1. Background and Study Rationale ............................................................................................. .....18
2.2. Benefit/Risk Assessment .................................................................................................... ........... 19
3. OBJECTIVES AND E NDPOINTS ..................................................................................................... 20
4. STUDY DESIGN ................................................................................................................. ............... 22
4.1. Overall Design............................................................................................................. ................... 22
4.2. Scientific Rationale for Study Design...................................................................................... ....... 24
4.2.1. Study-Specific Ethic al Design Considerations ........................................................................... 26
4.3. Justification for Dose..................................................................................................... ................. 26
4.4. End of Study Definition.................................................................................................... ............... 26
5. STUDY POPULATION ............................................................................................................. ......... 27
5.1. Inclusion Criteria ......................................................................................................... ................... 27
5.2. Exclusion Criteria ......................................................................................................... .................. 28
5.3. Prohibitions and Restrictions .............................................................................................. ........... 29
5.4. Screen Failures ............................................................................................................ .................. 29
6. STUDY INTERVENTION ........................................................................................................... ........ 30
6.1. Study Interventions Administered ........................................................................................... ....... 30
6.2. Preparation/Handling/ Storage/Accountability ................................................................................ 32
6.3. Measures to Minimize Bi as: Randomizati on and Blinding............................................................. 32
6.4. Study Interventi on Compliance .............................................................................................. ........ 33
6.5. Prohibited Medications..................................................................................................... .............. 33
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WIT HDRAWAL ............................................................................................... [ADDRESS_320795] udy Intervention ...................................................................................... ......33
7.1.1. Temporary Discontinuation of Study Intervention ...................................................................... 34
7.2. Participant Discontinuation/Wi thdrawal From the Study................................................................ 34
8. STUDY ASSESSMENTS AN D PROCEDURES ............................................................................... 35
8.1. Effectiveness Assessments .................................................................................................. ......... 35
8.1.1. KCCQ Scores .............................................................................................................. ............... 35
8.1.2. Actigraphy Measurements.................................................................................................. ........ 36
8.2. Exploratory Assessments.................................................................................................... ........... 36
8.2.1. Patient Global Impressi on of Change (PGIC) Scores ................................................................ 36
8.2.2. Patient Global Impression of Severity (PGI-S) Scores............................................................... 36
8.2.3. Participant Satisf action Survey........................................................................................... ........ 37
8.2.4. Healthcare Resource Ut ilization and Health  Economics............................................................ 37
8.3. Adverse Events and Serious Adve rse Events and Spec ial Situations .......................................... 37
8.3.1. Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event 
Information.................................................................................................................... .............. 38
8.3.2. Regulatory Reporting Requirement s for Serious Ad verse Events ............................................. 38
8.3.3. Pregnancy................................................................................................................ ................... 38
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 5
Approved, Date: [ADDRESS_320796]............................................................................................... ........... 38
9. STATISTICAL CONSIDERATIONS.................................................................................................. 39
9.1. Statistical Hypotheses..................................................................................................... ............... 39
9.2. Sample Size Determination .................................................................................................. ......... 39
9.3. Populations for Analyses................................................................................................... ............. 40
9.4. Statistical Analyses ....................................................................................................... ................. 40
9.4.1. Handling of Missing Data................................................................................................. ........... 40
9.4.2. Effectiveness Analyses................................................................................................... ............ 40
[IP_ADDRESS]. Primary and Secondary Effectiveness Analyses..................................................................... 40
[IP_ADDRESS]. Exploratory Analyses................................................................................................... ............ 41
9.4.3. Adverse Events Analysis .................................................................................................. .......... 41
9.4.4. Healthcare Resource Utilizat ion and Health Econo mics Analyses ............................................ 42
9.5. Interim Analysis........................................................................................................... ................... 42
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CO NSIDERAT IONS ............................ 43
10.1 Appendix 1: Abbreviations .................................................................................................. ........... 43
10.2 Appendix 2: Regulatory, Ethical, and Study Oversight C onsiderations......................................... 45
10.3 Appendix 3: Kansas City Cardio myopathy Questionnaire (KCCQ) ............................................... 53
10.4 Appendix 4: Patient Global Im pression of C hange (PGIC)............................................................ 57
10.5 Appendix 5: Patient Global Im pression of Severity (PGI-S) .......................................................... 58
10.6 Appendix 6: Participant Satisfaction Survey ................................................................................ ..59
10.7 Appendix 7: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting....................................................................................................... ........ 60
10.8 Appendix 8: Protocol Amendment History ..................................................................................... [ADDRESS_320797] OF IN-TEXT TABLES AND FIGURES
TABLES
Table 1: Effects of Sodium-glucose Cotransports-2 Inhibitors (SGLT-2is) on Heart Failure 
Outcomes....................................................................................................................... ........... 19
Table 2: Description of Study Interventions ..................................................................................... ....... 31
Table 3: Analysis Populations................................................................................................... .............. 40
FIGURES
Figure 1: Schematic Overview of the Study....................................................................................... ......11
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 6
Approved, Date: 23 February [ZIP_CODE]. PROTOCOL SUMMARY
1.1. Synopsis
Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure
Canagliflozin (JNJ-28431754) is an inhibitor of sodium-glucose co-transporter 2 (SGLT2) that has been 
developed as an oral antihyperglycemic agent (AHA) for the treatment of patients with type 2 diabetes 
mellitus (T2DM). The full chemical name [CONTACT_263792] (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-
2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate.
Canagliflozin therapy has been shown to improve clinical outcomes including hospi[INVESTIGATOR_263690] (HHF) in patients with T2DM and HF based on results from the CANVAS program (CANVAS 
[DIA3008]/CANVAS-Renal [DIA4003]) and CREDENCE [DNE3001] study. An improvement in 
patient’s symptoms of HF would be an importan t advance in the clinical management of HF. This 
randomized study is designed to assess whether canagliflozin therapy improves HF symptoms as assessed 
by [CONTACT_263730] (TSS) of the Kans as City Cardiomyopathy Questionnaire (KCCQ) 
patient-reported outcome (PRO) scale in participants with HF and with or without T2DM in a real-world 
setting.
OBJECTIVES AND ENDPOINTS
Primary Objective
The primary objective is:
! to determine the superiority of the effectivene ss of canagliflozin [ADDRESS_320798] key secondary objective is:
! to determine the superiority of the effectiveness of canagliflozin 100 mg daily versus placebo in 
improving the total daily step count.
The second key secondary objective is:
! to determine the superiority of the effectiveness of canagliflozin 100 mg daily versus placebo in 
improving the KCCQ individual domain scores (physical limitation, quality of life, clinical summary, 
and overall).
Exploratory Objectives
The exploratory objectives are to assess the effectivene ss of canagliflozin 100 mg daily in participants with 
symptomatic HF by:
! responses on the Patient Global Impression of Change  (PGIC) and the Patient Global Impression of 
Severity (PGI-S)
! healthcare resource utilization (HRU) and health economics data
! associations (correlations and/or categorical association measures) between digital markers (step count
and floors climbed), and clinical events such as need for outpatient intravenous therapi[INVESTIGATOR_014], emergency 
department (ED) visits, and hospi[INVESTIGATOR_602]
! daily floors climbed
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 7
Approved, Date: 23 February 2021! time to first hospi[INVESTIGATOR_059]/readmission for heart failure
! time to first hospi[INVESTIGATOR_059]/readmission for other events
! time to death
! the participant’s satisfaction with their experience with the virtual design at the end of the study.
Endpoints
The primary effectiveness endpoint is the change in KCCQ TSS from baseline to Month 3.
The key secondary effectiveness endpoints are 1) change in total daily step count from baseline to Month 
3, and 2) changes in KCCQ individual domain scores (physical limitation, quality of life, clinical summary, 
and overall) from baseline to Month 3.
The exploratory endpoints are the following:
! mean PGIC scores over time
! changes in PGI-S scores from baseline to Month 3
! change in number of daily floors climbed
! change in HRU and health economics data
! number of outpatient intravenous therapi[INVESTIGATOR_014], ED visits, and hospi[INVESTIGATOR_602]
! time to first hospi[INVESTIGATOR_059]/readmission for heart failure
! time to first hospi[INVESTIGATOR_059]/readmission for other events
! time to death
Adverse Event Data Collection
Due to the virtual method of data collection for this study, there will be 2 types of adverse event data 
collection, one by [CONTACT_263731]-report any adverse events to a call center, and the other by 
[CONTACT_263732]’s provider to their insurance system. Participant-
reported adverse events to the call center will be captured from the time of informed consent until 30 days after the end of treatment (ie, the last dose of st udy intervention) and adverse events from medical claims 
data from the time of informed consent to the end of study. After the treatment period plus 30 days, serious 
adverse events will be identified solely through medical claims data. Adverse events that occur during the 
treatment period plus 30 days identified from medical claims will be aggregated by [CONTACT_263733]. In addition, for this time period, self-reported adverse events from the call center will be summarized in a listing. Serious a dverse event data from medical claims for the 9-month 
study period will be aggregated by [CONTACT_15500].
Hypotheses
The primary hypothesis is that canagliflozin is superior to placebo as assessed by [CONTACT_263734] 3-month, double-blind treatment period.
OVERALL DESIGN
This is a randomized, double-blind, placebo-controlled, decentralized, virtual, interventional, superiority 
study conducted in the [LOCATION_002] (US) in participants with symptomatic HF (stratified by [CONTACT_263735] [HFrEF] and heart failure with preserved ejection fraction [HFpEF]) to 
examine the improvement in the KCCQ TSS after 3 months of treatment with canagliflozin 100 mg or 
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 8
Approved, Date: [ADDRESS_320799] 
participant follow-up in a real-world setting.
The study will enroll participants from large, integrated, health networks and large physician practices in 
the US with the participants conducting the majority  of their study-related activities through an app on a 
smartphone and actigraphy data from a Fitbit device. There will be no in-person clinic visits required by [CONTACT_1758].
The study consists of a screening period and a 3-month, double-blind treatment period. Approximately 
1,900 participants will be randomized into the study in a 1:1 ratio to canagliflozin 100 mg daily or placebo 
groups (950 in each study intervention group). After Month 3 (the end of the double-blind treatment period), 
the study will continue for an additional [ADDRESS_320800] clinically stable, symptomatic HF 
with or without T2DM with a KCCQ baseline overall summary score of ≤80 prior to randomization.
Study assessments include the KCCQ, Fitbit device data (step count and floors climbed), PGIC, PGI-S,
participant satisfaction survey, medical and pharmacy claims data (including up to 36 months history for eligibility confirmation), HRU and health economics (including hospi[INVESTIGATOR_059]/readmission due to HF or 
other reason, ED visits, the duration of stay at each hospi[INVESTIGATOR_059]/readmission), review of medical claims 
for prohibited medications and new diagnoses that may re quire discontinuation, dates of deaths, and adverse 
events.
NUMBER OF PARTICIPANTS
Approximately 1,900 participants will be randomized in th e study in a 1:1 ratio to canagliflozin 100 mg 
daily or placebo. Randomization of participants into th e study will be stratified by [CONTACT_263736] (ie, HFrEF or HFpEF) at study entry as recorded in the participant’s electronic health record (EHR).
INTERVENTION GROUPS AND DURATION
The total duration of study participation for each participant is approximately 9 months. Participants will 
be randomly assigned to receive canagliflozin 100 mg daily immediate-release over-encapsulated tablets 
(capsules) taken orally or placebo capsules for the duration of the 3-month, double-blind treatment period, followed by a 6-month, no treatment period during which data will continue to be collected.
Description of Interventions
The study intervention, JNJ-28431754 (canagliflozin), will be provided as immediate-release, 
over-encapsulated tablets (as a capsule) or a placebo capsule taken orally once daily for the duration of the 
3-month, double-blind treatment period.
Participant Unblinding
After each randomized participant completes the 3-month, double-blind treatment period of the study, they 
will be provided with their treatment allocation, wheth er they had been randomized to canagliflozin or 
placebo.
EFFECTIVENESS EVALUATIONS
Effectiveness evaluations include the KCCQ and daily step count.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 9
Approved, Date: 23 February 2021SECONDARY AND EXPLORATORY EVALUATIONS
Secondary and exploratory evaluations include K CCQ individual domains, PGIC, PGI-S, participant 
satisfaction survey, the HRU and health economics data collected in this study, time to death, and
associations (correlations and/or categorical association measures) between digital markers (step count and 
floors climbed) and clinical events such as need for outpatient intravenous therapi[INVESTIGATOR_014], ED visits, andhospi[INVESTIGATOR_602].
ADVERSE EVENT EVALUATIONSAdverse events will be captured through medical claims (from the time of informed consent to the end of 
study) and by [CONTACT_263737] (from the time of informed consent until 30 days after the end of treatment).
After the treatment period plus [ADDRESS_320801] a 
mean change from baseline of 3 points in the KCCQ TSS between canagliflozin 100 mg and placebo groups 
at 12 weeks. Assuming a significance level of 5% and a standard deviation of 18 points for mean change in KCCQ TSS, a total of 1,900 participants will be randomized in this study providing approximately 95% 
power. This sample size is adequate to account for a potential 5% dropout rate.
Effectiveness Analyses
Primary and Secondary Effectiveness Analysis
The primary and key secondary effectiveness analyses w ill be based on the intent-to-treat (ITT) analysis 
population (using all randomized participants).
As the KCCQ TSS is measured repeatedly over time (ie, at baseline, Weeks 4, 6, and 12 respectively), the 
primary effectiveness endpoint (change in KCCQ TSS from baseline to Month 3) will be analyzed by a 
mixed effect model repeated measures (MMRM) method simultaneously adjusting for study intervention
group, stratification factor (HFrEF versus HFpEF ), time, time by [CONTACT_228117], and baseline 
KCCQ TSS value as covariates. An unstructured covariance structure will be assumed across study 
intervention groups to model the within-participant e rrors. The primary comparison will be based on the 
difference in least squares means between treatments at Month 3. The treatment difference in the 
least-squares means and their 2-sided 95% confiden ce interval (CI) will be provided. An MMRM model 
accounts for data missing at random.
A responder analysis will also be performed when comparing proportions of participants with a 5- (or 10-) 
point improvement in KCCQ TSS from baseline between  the groups. This will be based on a two-sample 
difference in proportions test along with a 95% confidence interval for the difference in 2 proportions. 
Additionally, empi[INVESTIGATOR_263691].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 10
Approved, Date: 23 February 2021Subgroups defined by [CONTACT_654], gender, race and baseline disease/demographic characteristics will be 
pre-specified in the Statistical Analysis Plan (SAP) for the primary effectiveness analysis. Details about the 
imputation of any missing data will be provided in the SAP. Each subgroup will be analyzed following a 
similar MMRM model used in the analysis of the primary effectiveness endpoint (change in KCCQ TSS 
from baseline to Month 3). The treatment difference in the least-squares means and their 2-sided 95% CI 
will be provided from each subgroup analysis. Quantitative and/or qualitative interactions will be identified. 
Qualitative interactions will be investigated further by [CONTACT_263738].
The first key secondary endpoint of daily step count will be tested once the prima ry endpoi nt is shown to 
be significant at the 5% significance level using a two-si ded t-test. This approach will control for the overall 
Type I error rate at 5%.
For the second key effectiveness endpoint, an MMRM model (like that used in the analysis of the primary 
endpoint) will be employed to summarize changes in KCCQ individual domain scores (physical limitation, 
quality of life, clinical summary, and overall) from baseline to Month 3. This hypothesis will be independently tested at 5% without any control for overall Type I error rate.
Exploratory Analyses
Exploratory analyses include the following:
! summary statistics of PGIC and PGI-S scores
! associations (correlations and/or categorical association measures) between digital markers (step count
and floors climbed) and clinical events such as need for outpatient intravenous therapi[INVESTIGATOR_014], ED visits, 
and hospi[INVESTIGATOR_602]
! tabulation and comparison of total HRU and health economics data across groups
! descriptive statistics (eg, mean, median, and standard deviation) of daily floors climbed
! association between the KCCQ change from baseline to Month 3 and the PGIC at Month 3 will be 
examined and summarized
! time to death
! descriptive statistics of the participant's satisfaction with his/her experience with the virtual design at 
the end of the study.
Adverse Event Analyses
Adverse events reported to the call center will be assessed by [CONTACT_263739] (GMS) for 
causality and meeting suspected unexpected serious adverse reaction (S[LOCATION_003]R) reporting requirements. 
Self-reported adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA) and will be reported by [CONTACT_263740] T2DM and non-T2DM. Adverse events collected 
from medical claims will be categorized by [CONTACT_263741] T2DM and non-T2DM. 
Discontinuations will be summarized based on any av ailable data. Self-reported adverse events from the 
call center will be summarized in a listing.
Healthcare Resource Utilization (HRU) and Health EconomicsHealthcare Resource Utilization and health economics data will be descriptively summarized by [CONTACT_263742].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 11
Approved, Date: 23 February [ZIP_CODE].2. Schema
Figure 1: Schematic Overview of the Study

JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 14
Approved, Date: 23 February [ZIP_CODE]. INTRODUCTION
Canagliflozin (JNJ-28431754) is an inhibitor of sodium-glucose co-transporter 2 (SGLT2) that has 
been developed as an oral antihyperglycemic agent (AHA) for the treatment of patients with type 
2 diabetes mellitus (T2DM). The full chemical n ame for JNJ-28431754 is (1S) -1,5-anhydro-1-[3-
[[5-(4-fluorophenyl)-2-thienyl]methyl]- 4-methylphenyl]-D-glucitol hemihydrate.
The development program for canagliflozin has investigated the compound's efficacy and safety 
profile both as a monotherapy and in combination with other AHAs as adjunctive treatment to diet 
and exercise to improve glycemic control in the treatment of adult participants with T2DM. Three 
of the Phase 3 and Phase 4 studies evaluated canagliflozin in special populations, including older 
adults with T2DM and participants with T2DM who had moderate renal impairment. Recently 
completed cardiovascular (CV) safety studies ha ve evaluated canagliflozin as a treatment to reduce 
the risk of major adverse CV events (MACE - CV death, nonfatal myocardial infarction (MI), and 
nonfatal stroke) in adults with T2DM who have established cardiovascular disease (CVD) or at 
least 2 risk factors for CVD. Canagliflozin therapy has been shown to be associated with improved 
clinical outcomes in patients with T2DM and heart failure (HF) based on results from the 
CANVAS program (CANVAS [DIA3008] /CANVAS-Renal [DIA4003]) and CREDENCE 
[DNE3001] studies.
Proposed mechanisms of action of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and 
recent information from the DAPA-HF and DEFINE-HF studies16,21suggest that the effects of the 
SGLT2i class of medicines in patients with HF may extend to HF patients with or without T2DM.
This randomized study is designed to assess whether canagliflozin therapy improves HF symptoms 
as assessed by [CONTACT_263730] (TSS) of the Kansas City Cardiomyopathy Questionnaire 
(KCCQ) patient-reported outcome (PRO) scale in participants with HF and with or without T2DM
in a real-world setting.
CANVAS Heart Failure Data
Approximately 14.4% of all participants in the C ANVAS Program had a prior history of HF. While 
the CANVAS Program met its primary endpoint,15the principal secondary endpoint (superiority 
of canagliflozin with respect to reducing all-cause mortality) did not meet statistical significance, 
hence the results of the subsequent analys es examining endpoints including hospi[INVESTIGATOR_10889]
(HHF) must be viewed as exploratory. The hazard ratio (HR) for HHF in the combined 
canagliflozin group versus placebo was 0.67 (95% CI: 0.52, 0.87), with similar effects seen in the 
canagliflozin 100 mg and 300 mg groups in the CANVAS study.26These HR results resulted in 
choosing the lower dose of canagliflozin 100 mg for this study.
Canagliflozin lowered the risk of HHF in both patient groups: primary (participants with only risk 
factors for CV disease) (HR: 0.64; 95% CI: 0.35 to 1.15) and secondary (participants with a history 
of CV disease) (HR: 0.68; 95% CI: 0.51 to 0.90) with no evidence of statistical heterogeneity
(p=0.91).
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 15
Approved, Date: 23 February 2021An analysis of CANVAS26program demonstrated that canagliflozin decreased the risk of HHF in 
those with pre-existing history of HF (HR: 0.51; 95% CI: 0.33 to 0.78), and in those without a 
history of HF (HR: 0.79; 95% CI: 0.57 to 1.09) with no evidence of statistical heterogeneity
(p = 0.47). This effect of reducing the risk of HHF in those with or without a history of HF was 
consistent irrespective of established treatments for the prevention or management of HF 
(ie, inhibitors of the renin-angiotensin-aldosterone system, beta-blockers, and diuretics).
Therefore, a study to demonstrate that canagliflozin improves patient symptoms of HF would be 
an important advance in the clinical management of HF patients and would offer an important and 
valuable therapeutic option.
CREDENCE Study
The CREDENCE study (NDA [ADDRESS_320802] whether 
canagliflozin 100 mg, administered once daily, reduces the risk of kidney failure and CV events 
in participants with Stage 2 or 3 chronic kidney disease (eGFR ≥30 to <90 mL/min/1.73 m2) and 
macroalbuminuria (urinary ACR >300 to ≤5,000 mg/g) and T2DM who were receiving Standard 
of Care (SoC) therapy. SoC was defined in the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative consensus guidelines22and included a maximum tolerated labeled 
daily dose of an angiotensin-converting enzyme i nhibitor (ACEi) or angiotensin II receptor blocker 
(ARB). This study was conducted between [ADDRESS_320803] of canagliflozin relative to placebo in a population with established 
CKD and T2DM was measured using a composite endpoint of doubling of serum creatinine, 
progression to end-stage kidney disease (ESKD) (defined as dialysis, renal transplantation, or 
sustained eGFR <15 L/min/1.73 m2), and renal or CV death. The study also assessed the effects of 
canagliflozin on several adverse CV outcomes (CV death, HHF, nonfatal MI, nonfatal stroke, and 
hospi[INVESTIGATOR_10929]), and all-cause mortality. The results demonstrated clinical 
benefit of the 100 mg dose of canagliflozin in reducing important cardiovascular and renal clinical 
endpoints in patients with T2DM and impaired renal function.14Specifically, HHF (which was a 
secondary endpoint) was significantly decreased in the canagliflozin versus placebo group 
(HR=0.61 [0.47-0.80]). Additionally, the rate of amputation was not shown to be statistically 
significantly increased with canagliflozin treatment in the CREDENCE study in the overall 
population (HR=1.11 [0.79-1.37]).
Recently, INVOKANA®was approved as the only diabetes medicine indicated to reduce the risk 
of ESKD, worsening of kidney function, cardiovascular death, and HHF in adults with type 2 
diabetes and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine.
Use of SGLT2is in Heart Failure With or Without T2DM
A mechanistic basis has been proposed for the SGLT2i class of medicines to exert beneficial 
effects in HF irrespective of the diabetic state and effects on glycemic control or osmotic diuresis.25
Inhibition of sodium-hydrogen (Na/H) exchange in the kidney by [CONTACT_23265]2 inhibitors may reduce 
diuretic and endogenous natriuretic peptide resistance, and similar inhibition in the myocardium 
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 16
Approved, Date: 23 February 2021may lead to a reduction in cardiac injury, hypertrophy, fibrosis, remodeling, and systolic 
dysfunction. Furthermore, the major pathophysiological derangements of HF and a preserved 
ejection fraction may be mitigated by [CONTACT_263743]2 inhibitors to reduce blood pressure, 
body weight, and fluid retention as well as to improve renal function.25
The use of canagliflozin in patients without T2DM has been studied in approximately 1,200 healthy subjects in multiple Phase 1 studies. A thorough QT/QTc study in healthy subjects (study 
DIA1010 NDA 204042 Sequence 0000 Module [IP_ADDRESS]) demonstrated that canagliflozin at single 
therapeutic (300 mg) or supra-therapeutic (1,200 mg) doses does not lead to QT/QTc prolongation. 
At the 1,200 mg dose, canagliflozin C
maxwas approximately 1.4 times that for steady-state C maxat 
a 300 mg QD dose in T2DM subjects. This is important in light of the proarrhythmic myocardial 
substrate present in HF, in particular HFrEF, which is more prevalent in the non-type 2 diabetes 
population than in the type 2 diabetes population who experiences a higher incidence of HFpEF. 
For this study, the proposed dose of canagliflozin is 100 mg daily.
Additional evidence for the safety of canagliflozin in patients with HF comes from sub-group 
analyses of patients with T2DM in the CANVAS Program and in the CREDENCE study, in which 
there was no signal of increased arrhythmic death, or hyperkalemia – the latter of which is 
reassuring since many HF patients are on medications that are potassium-sparing, such as ACEis, 
ARBs, or mineralocorticoid receptor antagonists (MRAs), and diabetics are more predisposed to 
hyperkalemia with these agents than non-diabetics. CREDENCE in particular, which studied a 
population with a greater prevalence of kidney disease and a higher likelihood of hyperkalemia 
than the population in the CANVAS Program, demonstrated no increased incidence of 
hyperkalemia with canagliflozin versus placebo. In addition, in the CANVAS Program, there was 
no evidence of proportional differences in the risk of volume depletion, fracture, amputation, 
osmotic diuresis, acute kidney injury events, adverse events leading to discontinuation, and all 
serious adverse events (SAEs) between patients with or without HF at baseline (p interaction 
>0.160).26
A growing body of evidence is being generated for use of the SGLT2i class in HF. A randomized clinical study, DAPA-HF, in 4,774 HFrEF patients with (42%) and without (58%) T2DM
demonstrated safety consistent with the known profile of dapagliflozin.
16Ninety-four percent of 
patients were on ACEis or ARBs, and the mean eGFR was 66 mL/min/1.73m2. In the study, 
dapagliflozin met the primary composite endpoint with a statistically significant and clinically
meaningful reduction of cardiovascular death or the worsening of HF (defined as hospi[INVESTIGATOR_263692]), compared to placebo. Based on these data, dapagliflozin was recently 
approved by [CONTACT_2165] (FDA) to reduce the risk of CV death and 
hospi[INVESTIGATOR_263693] (NYHA class II-IV) with reduced 
ejection fraction with or without T2DM. This further supports more evaluations of this class of 
drugs in additional clinical trials in HFrEF and HFpEF, including measurement of symptomatic 
and functional improvement with tools such as the KCCQ.
Another recent randomized clinical study with dapagliflozin, DEFINE-HF in HFrEF, was 
completed in 510 patients w ith (62%) and without (36%) T2DM.21Results were consistent among 
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 17
Approved, Date: 23 February 2021patients with or without T2DM, including safety analyses. Mean eGFR was 69 mL/min/1.73m2. 
In the study, patients treated with dapagliflozin vs. placebo had clinically meaningful improvement 
in health status (KCCQ Overall Summary score &5 points).
Finally, there are multiple ongoing randomized studies with SGLT2 inhibitors in HF with or 
without T2DM (see below). As such, there is ample precedent to justify starting another study in 
HF patients irrespective of a diagnosis of T2DM.
Dapagliflozin:
!DEFINE-HF: biomarkers, symptoms, health status and quality of life in HFrEF patients (listed 
in clinicaltrials.gov March 2016)
!DELIVER: Outcomes study in HFpEF patients (listed in clinicaltrials.gov Aug. 2018)
!DETERMINE-REDUCED: Exercise capacity study in HFrEF patients (listed in 
clinicaltrials.gov March 2019)
!DETERMINE-PRESERVED: Exercise capacity study in HFpEF patients (listed in 
clinicaltrials.gov March 2019)
Empagliflozin:
!EMPEROR-Reduced: Outcomes study in HFrEF patients (listed in clinicaltrials.gov 
Feb. 2017)
!EMPEROR-Preserved: Outcomes study in HFpEF patients (listed in clinicaltrials.gov 
Feb. 2017)
!EMPERIAL-Reduced: Exercise capacity study in HFrEF patients (listed in clinicaltrials.gov 
Feb. 2018)
!EMPERIAL-Preserved: Exercise capacity study in HFpEF patients (listed in clinicaltrials.gov 
Feb. 2018)
Safety
The safety profile of canagliflozin is well established having been broadly evaluated for safety in 
several well-designed, randomized, clinical studies. The broader Phase 3/4 canagliflozin program 
was conducted in 22,645 patients, including 13,278 patients treated with canagliflozin and 
9,367 patients treated with a comparator, in 15 double-blind, controlled, clinical studies; among 
them, more than 1,100 patients reported a history of HF at baseline. In addition, there is an 
extensive, real-world base of adverse event reporting based on approximately 1,475,000,000 
person days treated worldwide. The SGLT2 inhibit or, dapagliflozin, was studied in HFrEF patients 
both with and without diabetes in the DAPA-HF and the DEFINE-HF studies16,21(those with 
HFrEF and type 2 diabetes). In those studies, the side effect profile was not different between those 
with or without T2DM or HF. Taken together, the evidence indicates that the safety profile of 
SGLT2 inhibitors, of which canagliflozin is a member, is well described and broadly understood 
in the study population included in this study.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 18
Approved, Date: [ADDRESS_320804] version of the Investigator's Brochure11and Addenda for JNJ-28431754 (canagliflozin).
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
The term “study intervention” refers to canagliflozin or placebo.2.1. Background and Study Rationale
Outcomes in studies of antidiabetic agents improving HF outcomes include canagliflozin, 
empagliflozin, and dapagliflozin CV that have shown a strong signal for improvement in HF 
endpoints with SGLT2i, but further studies are needed to validate these findings. However, very 
recently, the FDA approved dapagliflozin to reduce the risk of HHF in adults with T2DM and 
established CV disease or multiple CV risk fact ors. Based on results of the DECLARE-TIMI 58,
the possible role that SGTL2i may play in HF has been hypothesized but evaluation of the various 
pathways has not been performed.
[ADDRESS_320805] available therapy, is associated with poor patient outcomes.
23,24The 
CANVAS Program demonstrated that canagliflozin treatment in patients at cardiovascular (CV) 
risk was associated with improved clinical outcomes, including a reduction in the composite of 
CV death and HHF. A similar finding was observed with empagliflozin in the EMPA-REG
cardiovascular outcomes study and dapagliflozin in DECLARE-TIMI 58.19
A meta-analysis of EMPA-REG OUTCOME, CANVAS PROGRAM, and DECLARE-TIMI 58 looked at a total of 20,060 T2DM patients and the CV outcomes of SGLT2i therapi[INVESTIGATOR_014]. Enrolling 
3,891 HF patients at baseline, this meta-analysis demonstrated similar significant reduction in 
HHF, regardless of the patient’s baseline HF status (HR 0.68 vs HR 0.71) for those with or without 
HF. The benefit for these groups was affected only by [CONTACT_254488], with greater benefit observed 
in patients with lower estimated glomerular filtration rate (eGFR).
[ADDRESS_320806] similarity to reductions observed in randomized clinical 
studies and provide added confidence in the results of this meta-analysis.
27
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 19
Approved, Date: 23 February 2021This meta-analysis ( Table 1 ), as well as real-world data from CVD-REAL studies and the United 
States (US) Department of Defense Military Health  System, support the effect of an SGLT2i on 
reducing HF-related hospi[INVESTIGATOR_602]; however, they did not seek to differentiate or provide any 
insight on the effect of these therapi[INVESTIGATOR_263694] (HFrEF) 
and HFpEF phenotypes, defining the need for further investigation.20
Table 1: Effects of Sodium-glucose Cotransports-2 Inhibitors (SGLT-2is) on Heart Failure Outcomes
Nassif ME, Kosiborod M. Effects of sodium-glucose co-transporter type 2 inhibitors in heart failure. Diabetes Obes Metab. 
2019;21(Suppl. 2):19-23.
HFpEF is well recognized as the predominant type of HF in patients with T2DM and is possibly 
related to insulin resistance and obesity. Such predisposing factors are thought to be at the crux of 
ineffectiveness of traditional HF therapi[INVESTIGATOR_263695], making the need for 
impactful therapi[INVESTIGATOR_263696].2,6While more studies are 
underway, some encouraging data comes from the Canagliflozin for Japanese Patients with 
Chronic Heart Failure and Type II Diabetes (CANOSSA) study,28which assessed the effect of 
canagliflozin on Japanese patients with T2DM a nd stable HF. The study enrolled 35 patients, of 
which 33 had HFpEF, and focused on canagliflozin’s  effect of weight and adipose tissue reduction 
on these patients. Beyond reduction in glycated hemoglobin (HbA1c) and fat volumes, the study 
demonstrated reduction in oxidative stress, improved diastolic disfunction, and decrease in left 
ventricular mass, potentially linking canagliflozin use to an improved HFpEF condition.
In addition to showing an improvement in HHF, improvement in clinical symptoms, physical 
functioning and quality of life would be a highly important clinical outcome for patients with HF.
It is believed that canagliflozin, through its diur etic, blood pressure, and body weight  reduction 
effects would have a clinically meaningful imp act on these outcomes in these patients and 
represent an advance in the clinical management of th ese patients. This study is designed to assess 
whether canagliflozin can impact these importan t patient-centric outcomes not only in HFrEF 
patients but also in HFpEF patients for which there is no approved SGLT2i for treatment.
2.2. Benefit/Risk Assessment
Before randomization and throughout the study, the participant’s physician(s) will continue to 
manage the participant’s background medications to achieve goals for controlling the participant’s 
HF and T2DM (if present). Participants enrolled in this study will be managed based on the 
standards of care for HF and T2DM (if applicable) according to established local and regional 
guidelines. An Independent Scientific Advisory Committee comprised of experts in the 
management of patients with HF and sponsor representatives will be commissioned for this study. 
Other medications in the SGLT2i class of medicines are being studied in patients with HF with or 

JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 20
Approved, Date: 23 February 2021without T2DM as outlined in Section 2, Introduction; however, none of these agents are currently 
indicated for the clinical improvement in HF symptoms or for use in patients with HFpEF.
The risks of participation in the study include exposure to study intervention, with the potential for 
side effects. Participant safety will be assure d throughout the study by [CONTACT_263744] a call center to ask questions and to report adverse events. In addition, 
the adverse effect profile of canagliflozin has been well described and will be outlined in the 
informed consent form (ICF). In addition, participant prescribing information with a listing of 
potential adverse events will be sent to the participant in their welcome kit.
This study was designed based in general accordance with the FDA7and European Medicines 
Agency (EMA) guidance6on the development of medications and clinical investigations for the 
use of canagliflozin for the reduction of HF symptoms of HF and in consultation with Health 
Authorities. In addition, the design was also based on the FDA’s draft guidance to industry on drug 
development in HF which supports measures of patients’ symptoms and physical function as 
endpoints.8This study will be conducted under FDA Inve stigational New Drug (IND) regulations.
More detailed information about the known and expected benefits and risks of JNJ-28431754 
(canagliflozin) may be found in the Investigator’s Brochure, Canagliflozin.11
3. OBJECTIVES AND ENDPOINTS
OBJECTIVES
Primary Objective
The primary objective is:
!to determine the superiority of the effectiveness of canagliflozin [ADDRESS_320807] key secondary objective is:
!to determine the superiority of the effectiveness of canagliflozin 100 mg daily versus placebo 
in improving the total daily step count.
The second key secondary objective is:
!to determine the superiority of the effectiveness of canagliflozin 100 mg daily versus placebo 
in improving the KCCQ individual domain scores (physical limitation, quality of life, clinical summary, and overall).
Exploratory Objectives
The exploratory objectives are to assess the effectiveness of canagliflozin 100 mg daily in 
participants with symptomatic HF by:
[CONTACT_206178]-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 21
Approved, Date: 23 February 2021!responses on the Patient Global Impression of Change (PGIC) and the Patient Global 
Impression of Severity (PGI-S)
!healthcare resource utilization (HRU) and health economics data
!associations (correlations and/or categorical association measures) between digital markers 
(step count and floors climbed), and clinical events such as need for outpatient intravenous therapi[INVESTIGATOR_014], emergency department (ED) visits, and hospi[INVESTIGATOR_602]
!daily floors climbed
!time to first hospi[INVESTIGATOR_059]/readmission for heart failure
!time to first hospi[INVESTIGATOR_059]/readmission for other events
!time to death
!the participant's satisfaction with their experience with the virtual design at the end of the 
study.
ENDPOINTS
The primary effectiveness endpoint is the change in KCCQ TSS from baseline to Month 3.
The key secondary effectiveness endpoints are 1) cha nge in the daily step count from baseline to 
Month 3, and 2) changes in KCCQ individual domain scores (physical limitation, quality of life, 
clinical summary, and overall) from baseline to Month 3.
The exploratory endpoints are the following:
!mean PGIC scores over time
!changes in PGI-S scores from baseline to Month 3
!change in number of daily floors climbed
!change in HRU and health economics data
!number of outpatient intravenous therapi[INVESTIGATOR_014], ED visits, and hospi[INVESTIGATOR_602]
!time to first hospi[INVESTIGATOR_059]/readmission for heart failure
!time to first hospi[INVESTIGATOR_059]/readmission for other events
!time to death
Refer to Section 8, Study Assessments and Procedures for evaluations related to endpoints.
Adverse Event Data Collection
Due to the virtual method of data collection for this study, there will be 2 types of adverse event 
data collection, one by [CONTACT_263731] -report any adverse even ts to a call center, and 
the other by [CONTACT_263745]’s provider to their insurance 
system. Participant-reported adverse events to the call center will be captured from the time of 
informed consent until 30 days after the end of treatment (ie, the last dose of study intervention) 
and adverse events from medical claims data from the time of informed consent to the end of study.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 22
Approved, Date: 23 February 2021After the treatment period plus 30 days, serious adverse events will be identified solely through 
medical claims data. Adverse events that occ ur during the treatment period plus 30 days identified 
from medical claims will be aggregated by [CONTACT_263746]. In 
addition, for this time period, self-reported advers e events from the call center will be summarized 
in a listing. Serious adverse event data from medical claims for the 9-month study period will be 
aggregated by [CONTACT_15500].
HYPOTHESIS
The primary hypothesis is that canagliflozin is superior to placebo as assessed by [CONTACT_263747] 3-month, double-blind treatment period.
4. STUDY DESIGN
4.1. Overall Design
This is a randomized, double-blind, placebo-controlled, decentralized, virtual, interventional, 
superiority study conducted in the US in participants with symptomatic HF (stratified by [CONTACT_263748]) to examine the improvement in the KCCQ TSS after [ADDRESS_320808] participant follow-up in a real-world setting.
The study will enroll participants from large, integrated, health networks and large physician 
practices in the US with the participants conducting the majority of their study-related activities 
through an app on a smartphone and actigraphy data from a Fitbit device. There will be no 
in-person clinic visits required by [CONTACT_1758].
The study consists of a screening period and a 3-month, double-blind treatment period. 
Approximately 1,900 participants will be randomized into the study in a 1:1 ratio to canagliflozin 
100 mg daily or placebo groups (950 in each study intervention group). After Month 3 (the end of 
the double-blind treatment period), the study will continue for an additional [ADDRESS_320809] clinically stable, symptomatic 
HF (HFrEF or HFpEF) with or without T2DM with a KCCQ baseline overall summary score of
≤80 prior to randomization.
Participants should be receiving guideline recommended HF medications as prescribed by [CONTACT_170122](s) (such as ACEi, ARB, beta-adrenergic blocking agent or beta blocker 
[β-blocker], oral diuretics, MRA, angiotensin receptor-neprilysin inhibitor).
Study assessments include the KCCQ, Fitbit device data (step count and floors climbed), PGIC, 
PGI-S, participant satisfaction survey, medical and pharmacy claims data (including up to 
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 23
Approved, Date: 23 February 202136 months history for eligibility confir mation), HRU and health economics (including 
hospi[INVESTIGATOR_059]/readmission due to HF or other reason, ED visits, the duration of stay at each 
hospi[INVESTIGATOR_059]/readmission), review of medical claims for prohibited medications and new 
diagnoses that may require discontinuation, dates of deaths, and adverse events.
The total duration of study participation for each participant is approximately 9 months. 
Participants will be randomly assigned to receive canagliflozin 100 mg daily immediate-release 
over-encapsulated tablets (capsules) taken orally or placebo capsules for the duration of the 
3-month, double-blind treatment period, followed by a 6-month, no treatment period during which 
data will continue to be collected.
Participants will be enrolled from large, integrated, health networks or large physician practices 
who have electronic health records (EHR) to identify participants. The primary and secondary 
endpoint data collection will be done via an app for a smartphone (being developed specifically 
for the study) as well as data from the Fitbit device.
Data integrity will be assured by [CONTACT_263749] (Fitbit device, 
Fitbit app on smartphone, structured electronic PROs on smartphone via the study app, and 
medical claims data from or to payers) without manua l entry. Significant changes in actigraphy 
mid-study will be used to confirm that a Fitbit device remains associated with the participant to 
whom it is assigned. The Fitbit app on the participant’s phone will collect all data from the Fitbit 
device, and significant latencies between wearable sensor data uploads via the app will be used to 
identify any smartphone and Fitbit device dissociation. In addition, the participant will be informed 
during the consenting process that the study Fitbit de vice must only be paired to the participant’s 
smartphone and is to be used only by [CONTACT_2299].
There will be virtual study coordinating center support for initial participant onboarding to answer 
any study-related questions, assist with proper set up and use of the study app with the participant’s 
smartphone and Fitbit device/app as data collection tools, confirming drug receipt and compliance, 
and to collect participant-reported adverse events and report them to the sponsor. The virtual study 
coordinating center will help participants appropriately set up their devices for the purposes of the 
study. In this particular instance, the main requirement for the Fitbit device is maximal wear time, 
as all of the sensor data will be collected passively. The blinded study intervention will be hand 
delivered directly to the participants from a drug distribution vendor. No formal on-site monitoring 
of the study will be performed as this is a decentralized clinical study, however, the sponsors’ 
designee will centrally monitor participant medical claims, study app data, and Fitbit device data 
monthly for compliance with the study. For exampl e, monitoring will include detecting non-use 
of the study app or Fitbit device. Medical claims data will also be monitored for 
inclusion/exclusion criteria, adverse events, prohibited medications, HRU, relevant concomitant 
medications, and new diagnoses that would require discontinuation. In addition, the study app will 
send reminders to participants of study items to complete assessments (KCCQ, PGI-S, PGIC), and 
will collect weekly study drug compliance. If lack of participation is detected by [CONTACT_263750], the virtual study coordinating center will contact [CONTACT_263751]-up 
information.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 24
Approved, Date: 23 February 2021Participant Unblinding
After each randomized participant completes the 3-month, double-blind treatment period of the 
study, they will be provided with their treatment allocation, whether they had been randomized to 
canagliflozin or placebo.
A diagram of the study design is provided in Section 1.2, Schema.
4.2. Scientific Rationale for Study Design
Study Population
The study population selected represents participants with HF (HFrEF and HFpEF), with or 
without T2DM, who would potentially benefit from a drug intervention that could offer 
improvement in health status outcomes, such as clinical symptoms (eg, dyspnea and fatigue 
commonly experienced by [CONTACT_263752]) and impaired quality of life (eg, physical limitations 
and emotional dysfunction such as depression and anxiety). Participants who meet the inclusion 
criteria for these conditions include adults of any gender 18 years of age and older, representing 
the demographic group in which these conditions are prevalent, and mortality and hospi[INVESTIGATOR_263697], despi[INVESTIGATOR_263698].
Length of Study Periods
The screening period of 28 days allows for an appropriate length of time for screening procedures 
to determine study eligibility (with EHR re views, app set-up, completion of the KCCQ, and 
consenting). The baseline period of 7 days begins upon randomization and allows for shipment of 
the study drug and Fitbit device to the participant. The 3-month, double-blind treatment period 
provides sufficient timepoints for effectiveness assessments to demonstrate treatment differences 
between canagliflozin and placebo.
Placebo Control, Randomization, Blinding, Intervention Groups
A placebo control will be used to establish the frequency and magnitude of changes in clinical
endpoints that may occur in the absence of active intervention. Randomization will be used to 
minimize bias in the assignment of participants to intervention groups, to increase the likelihood 
that known and unknown participant attributes (eg, demographic and baseline characteristics) are 
evenly balanced across intervention groups, and to enhance the validity of statistical comparisons 
across intervention group. Blinded intervention will be used to reduce potential bias during data
collection and evaluation of clinical endpoints.
Dose and Dosage Administration Regimen
In the CANVAS program, canagliflozin reduced the relative risk of the composite of CV death or 
HHF compared with placebo, with a HR of canagliflozin versus placebo of 0.78 (95% CI: 0.67, 
0.91). The HRs were similar in the canagliflozin 100 and 300 mg groups. The HR for HHF in the 
combined canagliflozin group versus placebo was 0.67 (95% CI: 0.52, 0.87), with similar effects 
results seen in the canagliflozin 100 and 300 mg groups. These HR results resulted in choosing the 
lower dose of canagliflozin 100 mg daily for this study. In addition, because few participants
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 25
Approved, Date: 23 February 2021required titration to 300 mg/d in the CANVAS-R (DIA4003) study, and the treatment period in 
this study is relatively short, titration to the 300 mg/d dose is not necessary.
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Patient-reported outcomes (PROs) are a measurement tool for the symptom burden and functional 
limitations in patients with HF and have d emonstrated greater reproducibility than other clinical 
study measures like ejection fraction (EF) valve gradients,136-minute walk test, and a biomarker 
(B-type natriuretic peptide [BNP]).29The KCCQ (Section 10.3, Appendix 3) is a well-established 
PRO for use in patients with HF, with published validity and reliability. This instrument was 
developed and validated by [INVESTIGATOR_124]. John Spertus, the Lauer/Missouri Endowed Chair and Tenured 
Professor at the University of Missouri – Kansas City and the Clinical Director of Outcomes 
Research at Saint Luke’s Mid America Heart Institute. After reviewing its extensive psychometric 
profile, the KCCQ has been endorsed by [CONTACT_263753] a 
Certified Outcome Assessment through its Medical Device Development Tools Program.17In 
addition, the KCCQ was recently qualified by [CONTACT_263754] a 
PRO instrument for use in clinical investigations in heart failure.4
The KCCQ is a 23-item, self-administered questi onnaire and requires, on average, 4 to 6 minutes
to complete, with a resulting score of 0 to 100, and higher scores indicating better health. It was 
developed to measure the patient’s perception of their health status, including their HF symptoms, 
impact on physical and social function and how their HF impacts the quality of life. The KCCQ 
has been repeatedly used as a clinically meaningful outcome measure in CV research, patient 
management, and quality assessment. It has been extensively tested for its validity, reliability, and 
responsiveness improvement in participants with HF, and is well suited as the primary endpoint 
for this study. In addition, the intent of the study is to enroll participants with [LOCATION_001] Heart 
Association (NYHA) class II to IV. As it would be difficult to verify NYHA class with medical 
claims and EHR data, the sponsor will use a KCCQ overall summary score at baseline of ≤80, 
which is highly correlated to class II to IV in HFrEF and HFpEF based on the research published 
by [INVESTIGATOR_5951], et al.[ADDRESS_320810] on the participant’s daily activity.
Patient Global Impression of Change (PGIC)
The PGIC (Section 10.4, Appendix 4) is a commonly accepted, validated outcome measure used 
in clinical studies to assess the overall change in the participant’s status as it relates to the 
participant’s HF symptoms since starting the study as rated by [CONTACT_2299].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 26
Approved, Date: 23 February 2021Patient Global Impression of Severity (PGI-S)
The PGI-S (Section 10.5, Appendix 5) is a commonly accepted, validated outcome measure used 
in clinical studies to assess the change in the severity of the participant’s HF symptoms since 
starting the study as rated by [CONTACT_2299].
Health Resource Utilization and Health Economics Data Collection
Treatment of patients with symptomatic HF with JNJ-28431754 (canagliflozin) versus placebo
may result in lower utilization of any incident of hospi[INVESTIGATOR_059]/readmission due to HF or other 
reason, ED visits, the duration of stay at each hospi[INVESTIGATOR_059]/readmission, and discharge 
destination; therefore, comparison will be done across study intervention groups.
Participant Satisfaction Survey
Participants will be provided with an optional participant satisfaction survey at the end of the study 
to provide feedback on this virtual study and the use of the Fitbit device and smartphone to collect 
their information. This feedback may be important to consider when designing studies that use 
technology and devices.
4.2.1. Study-Specific Ethical Design Considerations
Potential participants will be fully informed of the risks and requirements of the study and, during 
the study, participants will be given any new infor mation that may affect their decision to continue 
participation, including availability of an approved medicine for HF in the same SGLT2i class of 
medicines as canagliflozin, which now includes the recent approval of dapagliflozin for HFrEF. 
They will be told that their consent to participate in the study is voluntary and may be withdrawn at 
any time with no reason given and without penalty or loss of benefits to which they would otherwise 
be entitled. Only participants who are fully able to understand the risks, benefits, and potential 
adverse events of the study, and provide their consent voluntarily will be enrolled.
4.3. Justification for Dose
Canagliflozin [ADDRESS_320811] ended the treatment period of the study (at 3 months), 
regardless of whether the participant has completed the study intervention, if he or she has 
completed assessments at Month 3 of the double-blind treatment period, withdrew earlier from the 
treatment, or died prior to the Month 3 assessment.
The end of study (at 9 months) is considered as the last visit shown in the Schedule of Activities 
for the last participant in the study. The final data from the study clinical research organization
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 27
Approved, Date: 23 February 2021partner will be sent to the sponsor (or designee) after completion of the collection of the study data 
from the Fitbit device and the claims in the time frame specified in the Trial Agreement.
5. STUDY POPULATION
Screening for eligible participants will be perfor med within [ADDRESS_320812] satisfy all of the following criteria to be enrolled in the study at 
enrollment (consent date):
1. any gender
2. 18 (or the legal age of consent in the jurisdiction in which the study is taking place)
years of age or older
3. Criterion modified per Amendment [ADDRESS_320813] clinically stable symptomatic HF (HFrEF or HFpEF)
For HFrEF:
a) EF≤40% AND
b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis 
code in any position in the past 18 months.
For HFpEF:
a) EF >40% AND
b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis 
code in any position in the past 18 months, AND
c) on a loop diuretic or spi[INVESTIGATOR_256813] (mineralocorticoid receptor
antagonists)1,3in the past 18 months.
4. Criterion modified per Amendment 2
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 28
Approved, Date: [ADDRESS_320814] a KCCQ baseline overall summary score of ≤[ADDRESS_320815] sole use (eg, not shared with other users) of smartphone compatible 
with the Fitbit device
7. willing/able to wear the Fitbit device on a regular basis for the 9-month study period
8. must sign an electronic informed consent form (eICF) indicating that he or she 
understands the purpose of, and procedures required for, the study and is willing to 
participate in the study, including follow-up.
5.2. Exclusion Criteria
Any potential participant who meets any of the following criteria prior to enrollment (consent date) 
will be excluded from participating in the study:
1. Criterion modified per Amendment [ADDRESS_320816] type 1 diabetes mellitus (T1DM)
3. Criterion modified per Amendment [ADDRESS_320817] acute decompensated HF (exacerbation of symptomatic HF) requiring 
intravenous diuretics, inotropes, or vasodilators within the last [ADDRESS_320818] stage 4 or 5 Chronic Kidney Disease (ie, eGFR <30ml/min on dialysis) from 
the most recent assessment
5. Criterion modified per Amendment [ADDRESS_320819] a diagnosis of hypotension within 30 days
7. Criterion modified per Amendment 2
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 29
Approved, Date: [ADDRESS_320820] any surgery, ie, cardiac surgery, planned 
during the 3-month treatment (except for minor surgery, ie, outpatient surgery under 
local anesthesia)
8. Criterion modified per Amendment [ADDRESS_320821] of the participant (eg, compromise the well-being) or that could
prevent, limit, or confound the protocol-specified assessments or have a life expectancy
of ∋[ADDRESS_320822] known allergies, hypersensitivity, or intolerance to JNJ-28431754 (canagliflozin)
or its excipi[INVESTIGATOR_840] (refer to Investigator's Brochure, Canagliflozin5)
10. be a woman participant who is pregnant, or breastfeeding, or planning to become
pregnant while enrolled in this study
11. are legally incompetent
12. Criterion modified per Amendment [ADDRESS_320823] device
14. patient identity or association with enrolling network cannot be verified
NOTE: The required source documentation to support meeting the enrollment criteria are noted 
in Section 10.2, Appendix 2: Regulatory, Ethical, and Study Oversight Considerations.
5.3. Prohibitions and Restrictions
Potential participants must be willing and able to adhere to the following lifestyle restrictions
during the course of the study to be eligible for participation:
1. Refer to details in Section 6.5, Prohibited Medications.
2. Agree to follow all requirements that must be met during the study as noted in the
Inclusion and Exclusion Criteria.
5.4. Screen Failures
Individuals who do not meet the criteria for participation in this study may be rescreened. 
Generally, a participant may only be rescreened once, but an additional screening may be allowed 
with concurrence by [CONTACT_456].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 30
Approved, Date: [ADDRESS_320824]-party representative. All data entered and collected 
via the study app with the participant’s smartphone and Fitbit device are time and date stamped 
for completeness. Those participants who electronically sign the remote e-consent but do not enroll 
in the study can be tracked up to the point that they no longer interact with the app. Reports will 
be available to permit a detailed listing of each participant from remote e-consent through the
study.
6. STUDY INTERVENTION
6.1. Study Interventions Administered
The study intervention, JNJ-28431754 (canagliflozin), will be provided as immediate-release,
over-encapsulated tablets (capsules) or placebo capsu les taken orally once daily before the first 
meal of the day for the duration of the 3-month, double-blind treatment period. The capsules should 
be swallowed intact and participants should not attemp t to dissolve them in water. The following 
table provides a description of the study interventions.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 31
Approved, Date: 23 February 2021Table 2: Description of Study Interventions
Group Name [CONTACT_26374] 1 Group 2
Study Intervention Name [CONTACT_263793]-encapsulated tablets (capsules) capsule
Unit Dose Strength 100 mg 0 mg
Dosage Level 100 mg 0 mg
Route of Administration oral oral
Use experimental placebo-comparator
Sourcing Provided centrally by [CONTACT_941] s ponsor Provided centrally by [CONTACT_941] s ponsor
Packaging and Labeling Individual participant bottles Individual participant bottles
Child resistant Child resistant
Brand Name [CONTACT_263794]®Not applicable
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 32
Approved, Date: 23 February 2021JNJ-28431754 (canagliflozin) will be manufactured and provided under the responsibility of the 
sponsor. Refer to the Investigator's Brochure, Canigliflozin11for a list of excipi[INVESTIGATOR_840].
6.2. Preparation/Handling/Storage/Accountability
All study intervention must be stored at c ontrolled temperatures ra nging from 20°C to  25°C (68°F 
to 77°F); excursions permitted between 15°C to 30° C (59°F to 86°F) and kept out of the reach of 
children.
The drug depot can refer to the pharmacy ma nual investigational product and procedures manual for 
additional guidance on study intervention preparation, handling, and storage.
The drug depot is responsible for ensuring that all study intervention received at the depot is 
inventoried and accounted for throughout the study. The dispensing of study intervention to the 
participant must be documented at the drug depot.
Study intervention must be handled in strict accordance with the protocol and the container label 
and must be stored at the drug depot in a secure area under appropriate environmental conditions.
Study intervention will be delivered to the participant by a qualified member of the drug 
depot/vendor. Study intervention will be supplied only to participants participating in the study. 
Participants will be instructed on how to store study intervention and how to destroy any unused 
study intervention at the end of the 3-month, double-blind treatment period.
6.3. Measures to Minimize Bias: Randomization and Blinding
Intervention Allocation
Procedures for Randomization and Stratification
Central randomization will be implemented in this study. Participants will be randomly assigned
to 1 of 2 study intervention groups based on a computer-generated randomization schedule 
prepared before the study by [CONTACT_263755].
Randomization will be balanced by [CONTACT_263756] 
(HFrEF or HFpEF) at study entry as recorded in the participant’s EHR.
The interactive web response system (IxR) will generate a randomization code, participant 
randomization number, and kit numbers once consent is completed and the participant is confirmed
eligible by [CONTACT_263757]. The kit number will dictate the study intervention 
assignment and the matching study intervention bottle(s) to be shipped to the participant directly 
from the drug distribution vendor.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 33
Approved, Date: 23 February 2021Blinding
The IxR will provide the kit number of the study intervention bottle(s) to be dispensed for each 
randomly assigned participant to begin dosing on Day [ADDRESS_320825] had their intervention assignment unblinded should continue to perform 
their scheduled evaluations.
6.4. Study Intervention Compliance
Participants will be instructed and notified by [CONTACT_263758]. Study intervention compliance data will be 
monitored bi-weekly and if compliance is not >80%, the participant will be contact[CONTACT_263759]-educate the participant on the importance of diary completion and taking study 
intervention daily.
6.5. Prohibited Medications
Prohibited medications include other SGLT2i medications (including commercially available 
canagliflozin); participants must not take any other investigational agents during the study.
Medications will be reviewed monthly through medical claims data by [CONTACT_36613].
The sponsor must be notified as soon as possible of any instances in which prohibited therapi[INVESTIGATOR_67693].
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study Intervention
A participant's study intervention must be discontinued during the 3-month, double-blind treatment 
period if:
!the participant has started another SGLT2i
!the participant has been diagnosed with T1DM
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 34
Approved, Date: 23 February 2021!for safety reasons or tolerability reasons (eg, advers e event), it is in the best interest of the 
participant to discontinue study intervention
!the participant develops severe renal impairment or End Stage Renal Disease, or is on dialysis
!the participant becomes pregnant
!the participant develops diabetic ketoacidosis
!the participant develops a new active skin ulcer, osteomyelitis, gangrene, or critical ischemia 
of the lower extremity or has an amputation.
The participant may choose to discontinue the study intervention only and remain in the study. In 
this case, the participant will continue to perform assessments (KCCQ, PGI-S, PGIC) and allow 
continued passive data collection from the app, Fitbit, and medical claims. If contact[CONTACT_263760], the call center or designee will inform the participant of the importance to the study and 
results to have ongoing ascertainment of assessments and vital status.
Additional information on informed consent for collection of vital status can be found in 
Section 10.2, Appendix 2: Regulatory, Ethical, and Study Oversight Considerations.
7.1.1. Temporary Discontinuation of Study Intervention
Study intervention may be temporarily discontinued; however, these interruptions should be kept 
to a minimum. Study intervention can be resumed when the participant, the virtual principal 
investigator, or the participant’s physician deems it is appropriate to do so.
7.2. Participant Discontinuation/Withdrawal From the Study
A participant will be withdrawn from the study for any of the following reasons:
!lost to follow-up
!withdrawal of consent
!death
In the event a participant withdraws consent and does not agree to any kind of follow-up and 
specifically refuses any further contact [CONTACT_263761], this must be documented 
in the study database. If a participant is lost to follow-up, vital status will still be attempted for 
collection at study end through the participant’s physician, medical claims, or public information 
according to local guidelines and as allowed by [CONTACT_427].
If a participant is lost to follow-up, every reasonable effort must be made by [CONTACT_263762] (eg, alive or dead) and the reason for 
discontinuation/withdrawal. This should include repeated telephone calls, certified letters, email 
requests, etc. The study screeners and app will obtain primary telephone contact [CONTACT_6227] (eg, 
smartphone numbers), as well as other contact [CONTACT_3031] (eg, email addresses) from participants
before randomization. In addition, the call center  should emphasize the importance of follow-up 
information to the participant before randomization. Fo llow-up can also be done with the help of 
the study site personnel. The measures taken to obtain follow-up information must be documented.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 35
Approved, Date: [ADDRESS_320826] to withdraw from the study should 
be asked if they agree to be contact[CONTACT_55883]-up information.
8. STUDY ASSESSMENTS AND PROCEDURES
Overview
The Schedule of Activities (SoA) summarizes the frequency and timing of effectiveness, medical 
resource utilization, health economic, and safety measurements applicable to this study.
Study-Specific Materials
The participants will be provided with the following supplies prior to starting the study:
!study intervention supply
!Fitbit device
!instruction manual(s) and patient drug information handouts.
8.1. Effectiveness Assessments
The primary effectiveness endpoint (KCCQ TSS) will  be assessed at baseline and Weeks 2, 4, 6, 
and 12 during the double-blind treatment period (first 3 months) and afterwards at 6 and 9 months 
when no study intervention is administered. The following sensor data will be obtained from the 
Fitbit: step count and floors climbed.
8.1.1. KCCQ Scores
The KCCQ is a 23-item, self-administered questionnaire on the study app and requires, on average, 
4 to 6 minutes to complete. It was developed to measure the patient’s perception of their health 
status, including their HF symptoms, impact on physical and social function and how their HF 
impacts the quality of life. It scored by [CONTACT_20526] a number for each response beginning with [ADDRESS_320827] half of the items within that 
domain are completed. Scale scores are transformed into values ranging from 0 to 100, with higher 
scores indicating more favorable health status.10
The answers provided by [CONTACT_263763]’s questions are used to calculate scores for the following 10 scales:
!Physical Limitation: a measure of how much a patient’s routine activities are hampered by 
[CONTACT_263764]
!Symptom Stability: a measure of whether a participant’s symptoms have changed over the 
past 2 weeks
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 36
Approved, Date: 23 February 2021!Symptom Frequency: a measure of how often a participant has HF symptoms
!Symptom Burden: a measure of how much the participant’s symptoms bother them
!Total Symptom: a combined measure of the symptom frequency and burden scales
!Social Limitation: a measure of how much a participant’s social and work activities are limited
by [CONTACT_263765]
!Self-Efficacy: a measure of how well a participant can manage her care, find answers and help
!Quality of Life: a measure of the overall impact of a participant’s HF on their perceived quality 
of life
!Clinical Summary: a combined measure of symptoms and physical limitations, congruent with 
the considerations a physician uses in assigning their NYHA classification
!Overall Summary: a combined measure of the participant’s physical limitation, total 
symptom, social limitation, and quality of life scores.
In this study, at screening/baseline, KCCQ overall summary score will be evaluated to determine 
participant eligibility into the study. All other KCCQ domains and summary scores will also be 
calculated at baseline and at subsequent post-baseline time points respectively.
8.1.2. Actigraphy Measurements
Once randomized into the study, data from the Fitbit device on each participant will be collected 
continuously pertaining to the total step counts and total floors climbed for the entire duration of 
the study. Actigraphy measures (ie, step counts and floors climbed) will be examined in relation 
to the PRO measures and clinical outcomes to better characterize treatment effect on daily activity.
8.2. Exploratory Assessments
8.2.1. Patient Global Impression of Change (PGIC) Scores
The PGIC is a global index that is used to rate the overall status of the participant related to the 
participant’s condition. It is rated by [CONTACT_263766], “Since the 
start of the treatment you’ve received in this study, your heart failure symptoms are”, where 1=very 
much improved, 2=somewhat improved, 3=a little improved, 4=no change, 5=a little worse, 
6=somewhat worse, and 7=very much worse. Refer to Section 10.4, Appendix 4: Patient Global 
Impression of Change (PGIC).
8.2.2. Patient Global Impression of Severity (PGI-S) Scores
The PGI-S is a global index that is used to rate the severity of a specific condition. It is rated by 
[CONTACT_263767], “Considering all aspects of your heart failure 
symptoms right now, would y ou say your heart failure symptoms are”, where 1=none, 2=mild, 
3=moderate, 4=severe, and 5=very severe. Refer to Section 10.5, Appendix 5: Patient Global 
Impression of Severity (PGI-S).
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 37
Approved, Date: 23 February [ZIP_CODE].2.3. Participant Satisfaction Survey
An optional participant satisfaction survey to assess the participant’s satisfaction with the virtual 
design of the study and use of the Fitbit device in the study will be provided to the participant at 
the end of study. Refer to Section 10.6, Appendix 6: Participant Satisfaction Survey.
8.2.4. Healthcare Resource Utilization and Health Economics
Healthcare Resource Utilization (HRU) and health economics data associated with medical 
encounters will be collected for all participants during the study. Protocol-mandated procedures, 
tests, and encounters are excluded. The data collected may be used to conduct exploratory 
economic analyses and will include:
!number and duration of first hospi[INVESTIGATOR_602]/readmissions (overall inpatient visit length of 
stay) for HF or any other reason
!number and duration of first hospi[INVESTIGATOR_602]/readmissions (overall inpatient visit length of 
stay) for any other events
!number of emergency room visits
!discharge destination
8.3. Adverse Events and Serious Adverse Events and Special Situations
Participants will be instructed to self-report any adverse events to a call center. In addition, this 
information may be discovered by [CONTACT_263768]. Once 
identified, the call center will complete and submit a solicited safety reporting form to Janssen 
Global Medical Safety (GMS) per the sponsor’s standard operating procedure. Queries for these 
cases will go to the call center/and virtual principal investigator [CONTACT_106967]. If follow-up is needed with the participant’s treating physician, it will be done either through the virtual principal 
investigator, who may contact [CONTACT_12682] n directly, as agreed upon in the ICF. All SAEs
will be assessed by [CONTACT_263769] 
(S[LOCATION_003]Rs) for expedited regulatory reporting.
Medical claims adverse event data will be reviewed and evaluated including potential S[LOCATION_003]R 
assessment and regulatory reporting in aggregate at the end of the 3-month, double-blind treatment 
period when the unblinded data are available. In addition, for this time period, self-reported 
adverse events from the call center will be summarized in a listing. Serious adverse event data 
from medical claims for the 9-month study period will be aggregated by [CONTACT_15500].
Self-reported adverse events will be coded according to the Medical Dictionary for Regulatory 
Activities (MedDRA) and will be reported by [CONTACT_263770] T2DM and non-T2DM. 
Adverse events collected from medical claims will be aggregated based on diagnosis codes for the 
incidences of non-endpoint SAEs (ie, SAEs leading to hospi[INVESTIGATOR_602], ED visits) and adverse 
events of interest between groups reported by T2DM and non-T2DM. Discontinuations will be 
summarized based on any available data.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 38
Approved, Date: 23 February [ZIP_CODE].3.1. Time Period and Frequency for Collecting Adverse Event and Serious 
Adverse Event Information
All Adverse Events
Adverse events will be captured through medical claims (from the time of informed consent to the 
end of study) and by [CONTACT_263737] (from the time of informed consent until 30 days after the end 
of treatment). After the treatment period plus 30 days, serious adverse events will be identified 
solely through medical claims data. Adverse events that occur during the treatment period plus 
30 days identified from medical claims will be aggregated by [CONTACT_263729]. In addition, for this time period, self-reported adverse events from the call 
center will be summarized in a listing. Serious adverse event data from medical claims for the 
9-month study period will be aggregated by [CONTACT_15500].
8.3.2. Regulatory Reporting Requirements for Serious Adverse Events
The sponsor assumes responsibility for appropriate reporting of adverse events to the regulatory 
authorities. The sponsor will also report to the virtual principal investigator (and the head of the 
investigational institute where required) all S[LOCATION_003]Rs. The virtual principal investigator (or sponsor 
where required) must report S[LOCATION_003]Rs to the appropriate Independent Ethics 
Committee/Institutional Review Board (IEC/IRB) th at approved the protocol unless otherwise 
required and documented by [CONTACT_6179]/IRB. A S[LOCATION_003]R will be reported to regulatory authorities 
unblinded. The virtual principal investigator [INVESTIGATOR_263699]/IRB will receive a blinded S[LOCATION_003]R summary, 
unless otherwise specified.
8.3.3. Pregnancy
Female participants and male participants with a partner becoming pregnant will be instructed to 
call the call center for any pregnancy. The call center will report the pregnancy to the sponsor 
within 24 hours of their knowledge of the event using the appropriate pregnancy notification form. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered adverse events and must also be self-reported by [CONTACT_263771]. Any participant who becomes pregnant during the study must be 
promptly discontinued from the study intervention.
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required.
8.3.4. Adverse Events of Interest
Adverse events of interest include all severe hypoglycemic events, acute kidney injury, fractures, 
diabetic ketoacidosis, and lower limb amputation.
In addition, the following adverse events will be examined: hypotension; Fournier’s gangrene; 
genital mycotic infections; urinary tract infections (including urosepsis and pyelonephritis); 
increased urination; and hypersensitivity reactions including angioedema and anaphylaxis.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 39
Approved, Date: 23 February [ZIP_CODE]. STATISTICAL CONSIDERATIONS
Statistical analysis will be done by [CONTACT_35522]. A general 
description of the statistical methods to be used to analyze the effectiveness and safety data is 
outlined below. Specific details will be provided in the SAP.
The primary study objective will be addressed by [CONTACT_263772] 3 between the study intervention groups. The key secondary study objective 
will involve a comparison between the 2 randomized groups in terms of the mean difference in 
daily step counts from baseline to Month 3. F or analyzing the primary, secondary, and exploratory 
objectives, an intent-to-treat (ITT) population comprising of all randomized participants will be 
used. Specific imputation rules for missing data (eg, missing KCCQ TSS, daily step count) will be 
applied, if warranted, and will be specified in the SAP before the final database lock. Descriptive 
statistics such as mean, median, standard deviation, interquartile range, minimum and maximum 
will be used to summarize continuous variables. Counts and proportions will be used to summarize 
categorical variables. Graphical data displays (eg, box plots) may be employed to summarize data. 
For time to event variables, Kaplan-Meier estimates  over time will be plotted. All statistical tests 
will be two-sided and performed at the 5% significance level unless otherwise specified. No 
multiplicity adjustment to the overall Type I error rate will be applied when analyzing the 
exploratory variables.
9.1. Statistical Hypotheses
For the primary effectiveness endpoint, the null hypothesis is that the canagliflozin [ADDRESS_320828] a mean change from baseline of 3 points in 
the KCCQ TSS between canagliflozin 100 mg and placebo groups at 12 weeks. Assuming a 
significance level of 5% and a standard deviation of 18 points for mean change in KCCQ TSS, a 
total of 1,900 participants will be randomized in this study providing approximately 95% power. 
This sample size is adequate to account for a potential 5% dropout rate.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 40
Approved, Date: 23 February [ZIP_CODE].3. Populations for Analyses
For purposes of analysis, the following populations are defined:
Table 3: Analysis Populations
Population Description
Enrolled All participants who sign the ICF
Intent-to-Treat 
(ITT)All randomized participants
Per Protocol 
(PP)A subset of the ITT population. Randomized participants who received study drug and with 
major protocol deviations will be excluded from the PP population. Major protocol deviations 
will be defined in the SAP.
9.4. Statistical Analyses
9.4.1. Handling of Missing Data
Missing data affecting the primary endpoint change  in KCCQ TSS will be addressed via the 
MMRM method that assumes missingness at random (MAR). Specific imputation rules including 
statistical modeling approaches may be employed when such an assumption is not valid. In cases 
where individual items in the KCCQ domains are missing or not completed at required times, 
appropriate rules to impute missing item scores will be specified based on the KCCQ manual. 
Sensitivity analyses will be conducted to assess impact of missing data on key study results. 
Further details about the imputation rules and sensitivity analyses will be provided in the SAP.
9.4.2. Effectiveness Analyses
[IP_ADDRESS]. Primary and Secondary Effectiveness Analyses
The primary and key secondary effectiveness anal yses will be based on the ITT analysis population 
(using all randomized participants).
As KCCQ TSS is measured repeatedly over time (ie, at baseline, Week 2, Week 4, Week 6, and 
Week 12 respectively), the primary effectiveness endpoint (change in KCCQ TSS from baseline 
to Month 3) will be analyzed by a mixed effect model repeated measures (MMRM) method 
simultaneously adjusting for study intervention group, stratification factor (HFrEF versus HFpEF), 
time, time by [CONTACT_228117], and baseline KCCQ TSS value as covariates. An 
unstructured covariance structure will be assumed across study intervention groups to model the 
within-participant errors. The primary comparison will be based on the difference in least squares 
between treatments at Month 3. The treatment difference in the least squares means and their 2-
sided 95% confidence interval (CI) will be provi ded. An MMRM model accounts for data missing 
at random.
A responder analysis will also be performed when comparing proportions of participants with a 5-
(or 10-) point improvement in KCCQ TSS from baseline between the study intervention groups. 
This will be based on a two-sample difference in proportions test along with a 95% confidence 
interval for the difference in 2 proportions. Additionally, empi[INVESTIGATOR_263700].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 41
Approved, Date: 23 February 2021The primary effectiveness endpoint will also be analyzed by [CONTACT_263773], gender, 
race and key baseline disease/demographic characteristics using the MMRM approach described 
above. Further details will be provided in the SAP. Quantitative and/or qualitative interactions for 
each subgroup and treatment will be identified. Qualitative interactions will be investigated further 
by [CONTACT_263774]9and interpreted accordingly.
The first key secondary endpoint of daily step count will be tested once the primary endpoint is 
shown to be significant at the 5% significance level using a two-sided t-test. This approach will 
control for the overall Type I error rate at 5%.
For the second key effectiveness endpoint, an MMRM model (like that used in the analysis of the 
primary endpoint) will be employed to summarize changes in KCCQ individual domain scores 
(physical limitation, quality of life, clinical summary, and overall) from baseline to Month 3. This 
hypothesis will be independently tested at 5% without any control for overall Type I error rate.
[IP_ADDRESS]. Exploratory Analyses
Exploratory analyses will be performed with no adjustment for multiplicity and include the 
following:
!summary statistics of PGIC and PGI-S scores
!associations (correlations and/or categorical association measures) between digital markers 
(step count and floors climbed) and clinical events such as need for outpatient intravenous therapi[INVESTIGATOR_014], ED visits, and hospi[INVESTIGATOR_602]
!tabulation and comparison of total HRU and health economics data across groups.
!descriptive statistics (eg, mean, median, and standard deviation) of daily floors climbed
!association between the KCCQ change from baseline to Month 3 and the PGIC at Month 3 
will be examined and summarized
!time to death
!descriptive statistics of the participant's satisfaction with his/her experience with the virtual 
design at the end of the study.
9.4.3. Adverse Events Analysis
Adverse events reported to the call center will be assessed by [CONTACT_263775]. Self-reported  adverse events will be coded according to 
MedDRA and will be reported by [CONTACT_263740] T2DM and non-T2DM. Adverse events 
collected from medical claims will be aggregated based on diagnosis codes for the incidences of 
non-endpoint SAEs (ie, SAEs leading to hospi[INVESTIGATOR_602] , ED visits) and adverse events of interest 
between groups reported by T2DM and non-T2DM. Discontinuations will be summarized based 
on any available data. Adverse events reported from the call center will be reported separately 
from those obtained from the medical claims data. Self-reported adverse events from the call center 
will be summarized in a listing.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 42
Approved, Date: 23 February [ZIP_CODE].4.4. Healthcare Resource Utilization and Health Economics Analyses
Healthcare resource utilization (HRU) and health economics data will be descriptively summarized 
by [CONTACT_65237].
9.5. Interim Analysis
No interim analysis is planned for this study.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 43
Approved, Date: 23 February 202110. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 Appendix 1: Abbreviations
ACEi angiotensin-converting enzyme inhibitor
AE adverse event
AHA antihyperglycemic agent
ARB angiotensin II receptor blocker
ARNi angiotensin receptor-neprilysin inhibitorBB
beta blocker
CANVAS short title for study, Canagliflozin Cardiovascular Assessment StudyCANVAS-R short title for study, Canagliflozin Cardiovascular Assessment Study-Renal
CI confidence interval
CREDENCE short title for study, Canagliflozin and Renal Events in Diabetes with Established Nephropathy 
Clinical Evaluation Trial
CV cardiovascularCVD cardiovascular diseaseDKA diabetic ketoacidosis
DMC Data Monitoring Committee
ED emergency department
EHR electronic health recordEMPA empagliflozin
ESKD End Stage Kidney Disease
GCP Good Clinical Practice
GMS Global Medical SafetyHF heart failureHFpEF heart failure with 
preserved ejection fraction
HFrEF heart failure with reduced ejection fractionHHF hospi[INVESTIGATOR_263701]-to-treatIxR interactive web response system
KCCQ Kansas City Cardiomyopathy Questionnaire
MACE major adverse cardiovascular events
MAR missing at random
MDDT Medical Device Development Tools
MedDRA Medical Dictionary for Regulatory Activities
MI myocardial infarctionMMRM mixed effect model repeated measure
NYHA [LOCATION_001] Heart Association
PGIC Patient Global Impression of Change
PGI-S Patient Global Impression of Severity
PQC Product Quality Complaint
PRO patient-reported outcome(s) (paper)
SAE serious adverse eventSAP statistical analysis plan
SGLT2 sodium-glucose co-transporter 2
SGLT2i sodium-glucose co-transporter 2 inhibitor
SoA schedule of activities
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 44
Approved, Date: 23 February 2021S[LOCATION_003]R suspected unexpected serious adverse reaction
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TSS Total Symptom ScoreUS [LOCATION_002]
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 45
Approved, Date: 23 February 202110.2 Appendix 2: Regulatory, Ethical, and Study Oversight Considerations
REGULATORY AND ETHICAL CONSIDERATIONS
Virtual Principal Investigator [INVESTIGATOR_263702], current ICH guidelines on Good Clinical Practice (GCP), and 
applicable regulatory and country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human participants. 
Compliance with this standard provides public assurance that the rights, safety, and well-being of 
study participants are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study data are credible.
Protocol Amendments
The sponsor will not modify this protocol without a formal amendment by [CONTACT_456]. All 
protocol amendments must be issued by [CONTACT_456]. Protocol amendments must not be 
implemented without prior IEC/IRB approval, or when the relevant competent authority has raised 
any grounds for non-acceptance, except when necessary to eliminate immediate hazards to the 
participants, in which case the amendment must be promptly submitted to the IEC/IRB and 
relevant competent authority. When the change(s) involve only logistic or administrative aspects 
of the study, the IEC/IRB (where required) only needs to be notified.
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the virtual principal investigator [INVESTIGATOR_263703](s), which will be provided as a separate document. Except 
in emergency situations, this contact [CONTACT_90815]. In all cases, contact [CONTACT_263776]. These will be recorded by [CONTACT_456].
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities 
in each respective country, if applicable. A study may not be initiated until all local regulatory 
requirements are met.
Required Prestudy Documentation
The following documents must be provided to th e sponsor before shipment of study intervention 
to the drug depot:
! protocol and amendment(s), if any, signed and dated by [CONTACT_458]
! a copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if applicable, participant compensation progr ams. This approval must clearly identify the 
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 46
Approved, Date: [ADDRESS_320829] be signed (or sealed, where appropriate per 
local regulations) by [CONTACT_23851].
! name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and their 
function, with a statement that it is organized and operates according to GCP and the applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/IRB, a general statement may be substituted for this list. If the principal investigator [CONTACT_832] a member of the IEC/IRB, documentation must be obtained to state that this person did not participate in the deliberations or in the vote/opi[INVESTIGATOR_23748].
! regulatory authority approval or notification, if applicable
! signed and dated statement of virtual principal investigator (eg, Form FDA 1572) and current 
curriculum vitae (CV), if applicable
! documentation of virtual principal investigator [INVESTIGATOR_263704] (eg, curriculum 
vitae)
! completed virtual principal investigator [INVESTIGATOR_263705], where required
! signed and dated clinical trial agreement, which includes the financial agreement
! any other documentation required by [CONTACT_427].
The following documents must be provided to the sponsor before enrollment of the first
participant:
! completed virtual principal investigator [INVESTIGATOR_263706]
! documentation of virtual principal investigator [INVESTIGATOR_263704] (eg, curriculum 
vitae).
Independent Ethics Committee or Institutional Review Board
Before the start of the study, the virtual principal investigator [INVESTIGATOR_1461] (or sponsor where 
required) will provide the IEC/IRB with current and complete copi[INVESTIGATOR_23747] 
(as required by [CONTACT_427]):
! final protocol and, if applicable, amendments
! sponsor-approved ICF (and any other written materials to be provided to the participants)
! Investigator's Brochure, Canigliflozin
11(or equivalent information) and amendments/addenda
! sponsor-approved participant recruiting materials
! information on compensation for study-related injuries or payment to participants for 
participation in the study, if applicable
! virtual principal investigator [INVESTIGATOR_263707] (unless 
not required, as documented by [CONTACT_6179]/IRB)
! information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for participants
! any other documents that the IEC/IRB requests to fulfill its obligation.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 47
Approved, Date: 23 February 2021This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely administrative, with no consequences for 
participants, data or study conduct, unless required locally), the ICF, applicable recruiting 
materials, and participant compensation programs, and the sponsor has received a copy of this 
approval. This approval letter must be dated and must clearly identify the IEC/IRB and the 
documents being approved.
During the study, the principal investigator (or sponsor where required) will send the following 
documents and updates to the IEC/IRB for their review and approval, where appropriate:
! protocol amendments (excluding the ones that are purely administrative, with no 
consequences for participants, data or study conduct)
! revision(s) to ICF and any other written materials to be provided to participants
! if applicable, new or revised participant recruiting materials approved by [CONTACT_456]
! new edition(s) of the Investigator's Brochure, Canigliflozin11and amendments/addenda
! summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annually)
! reports of adverse events that are of interest, special interest, serious, unlisted/unexpected, and 
associated with the study intervention
! new information that may adversely affect the safety of the participants or the conduct of the 
study
! deviations from or changes to the protocol to eliminate immediate hazards to the participants
! report of deaths of participants under the virtual principal investigator's care
! notification if a new virtual principal investigator [INVESTIGATOR_263708]
! development Safety Update Report and Line Listings, where applicable
! any other requirements of the IEC/IRB.
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for participants, data or study conduct), the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study, where required.
At the end of the study, the virtual principal i nvestigator or designee (or sponsor where required) 
will notify the IEC/IRB about the study completion (if applicable, the notification will be 
submitted through the head of investigational institution).
Other Ethical Considerations
For study-specific ethical design considerations, refer to Section 4.2.1 .
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 48
Approved, Date: 23 February 2021FINANCIAL DISCLOSURE
The virtual principal investigator [INVESTIGATOR_263709], accurate 
financial information in accordance with local regulations to allow the sponsor to submit complete 
and accurate financial certification or disclosure statements to the appropriate regulatory 
authorities. The virtual principal investigator [INVESTIGATOR_263710] 1 year after completion of the study.
Refer to Required Prestudy Documentation (above) and contracts for details on financial 
disclosure.
INFORMED CONSENT (REMOTE E-CONSENT) PROCESS
Each participant must give remote e-consent according to local requirements after the nature of 
the study has been fully explained. The remote e-consent must be electronically signed within the 
study app before the performance of any study-related activity. The remote e-consent that is/are 
used must be approved by [CONTACT_263777] a language that 
the participant can read and understand. The remote e-consent should be in accordance with 
principles that originated in the Declaration of Helsinki, current ICH and GCP guidelines, 
applicable regulatory requirements, and sponsor policy. After having obtained the consent, a copy 
of the remote e-consent must be sent to the participant.
In this study, a remote e-consent process will be utilized. Before enrollment in the study, the 
participant will have an opportunity to read through the remote e-consent which will detail the 
aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any 
discomfort participation in the study may entail. The remote e-consent will explain that their 
participation is voluntary and that they may withdraw consent to participate at any time. They will 
be informed that choosing not to participate will not affect the care they will receive. Finally, they 
will be told that their records may be accessed by [CONTACT_263778], to the extent permitted by [CONTACT_6983](s) 
or regulations. By [CONTACT_263779] e-consent the participant is authorizing such 
access, which includes permission to obtain information about his or her survival status. It also 
denotes that they are agreeing to allow recontact [CONTACT_263780], if needed.
If the participant has any questions about the study related to the remote e-consent process prior 
to providing their electronic signature, they will be provided with an opportunity to discuss these 
questions with the virtual principal investigator [INVESTIGATOR_121377]/or a contact [CONTACT_263781]. 
Once the participant understands all aspects of the remote e-consent, consent should be 
appropriately recorded by [CONTACT_67824]’s personally dated signature [INVESTIGATOR_145907]. After having obtained the consent, the participant will receive a copy of the remote 
e-consent via email (after the participant has verified his or her email address) for their records.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 49
Approved, Date: [ADDRESS_320830]. 
Sponsor personnel whose responsibilities require access to  personal data agree to keep the identity 
of participants confidential.
The informed consent obtained from the participant includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her original medical 
records (source data/documents) for study-related monitoring, audit, IEC/IRB review, and 
regulatory inspection. This consent also addresses the transfer of the data to other entities.
The participant has the right to request through the virtual principal investigator [INVESTIGATOR_263711]. 
Reasonable steps will be taken to respond to such a request, taking into consideration the nature 
of the request, the conditions of the study, and the applicable laws and regulations.
COMMITTEES STRUCTURE
An Independent Scientific Advisory Committee comprised of experts in the management of 
patients with HF and sponsor representatives will be commissioned for this study. Committee 
membership and responsibilities will be documented in the committee charter(s).
PUBLICATION POLICY/DISSEMINATION OF CLINICAL STUDY DATA
All information, including but not limited to information regarding JNJ-28431754 (canagliflozin)
or the sponsor's operations (eg, patent application, formulas, manufacturing processes, basic 
scientific data, prior clinical data, formulation information) supplied by [CONTACT_263782], and any data, generated as a result of this study, are
considered confidential and remain the sole property of the sponsor. The virtual principal 
investigator [INVESTIGATOR_263712]'s prior written 
consent.
The virtual principal investigator [INVESTIGATOR_263713]-28431754 
(canagliflozin), and thus may be disclosed as required to other clinical investigators or regulatory 
agencies. To permit the information derived from the clinical studies to be used, the virtual 
principal investigator [INVESTIGATOR_263714].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 50
Approved, Date: [ADDRESS_320831] udy will be used to determine a coordinating 
investigator [INVESTIGATOR_25810], if appropriate.
Study participant identifiers will not be used in publication of results. Any work created in 
connection with performance of the study and contained in the data that can benefit from copyright 
protection (except any publication by [CONTACT_40999]) shall be the property 
of the sponsor as author and owner of copyright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data and 
information without approval from the virtual principal investigator. The virtual principal 
investigator [INVESTIGATOR_263715]. If the virtual principal 
investigator [INVESTIGATOR_263716], a copy of the manuscript must be 
provided to the sponsor for review at least [ADDRESS_320832] made a significant contribution to the conception or design of the work; 
or the acquisition, analysis, or interpretation of the data for the work; and drafted the work or 
revised it critically for important intellectual content; and given final approval of the version to be 
published; and agreed to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately investigated and 
resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence and the results of clinical studies as required 
by [CONTACT_2371].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 51
Approved, Date: [ADDRESS_320833] be available for the following: participant 
identification, eligibility, and study identification; record of all adverse events and follow-up of 
adverse events; and date of study completion and reason for early discontinuation of study 
intervention or withdrawal from the study, if applicable. Many of the assessments in this study 
(date of signed informed consent, activity data, KCCQ data) will be collected directly from the 
participant and therefore the data received is from a direct source.
The author of an entry in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the virtual principal investigator [INVESTIGATOR_263717].
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_67833] (eg, baseline KCCQ) and 
documented in the source documents.
RECORD RETENTION
In compliance with the ICH/GCP guidelines, the virtual principal investigator/call center will 
maintain all source documents that support the data collected from each participant, as well as all 
study documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study documents as specified by [CONTACT_8146](s). 
The virtual principal investigator/call center will take measures to prevent accidental or premature 
destruction of these documents.
Essential documents must be retained until at least [ADDRESS_320834]. These documents will be retained for a longer period 
if required by [CONTACT_263783]. It is the 
responsibility of the sponsor to inform the virtual principal investigator/call center as to when these 
documents no longer need to be retained.
If the virtual principal investigator [INVESTIGATOR_1496], relocates, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will accept 
the responsibility. The sponsor must be notified in writing of the name [CONTACT_66903]. Under no circumstance shall the virtual principal investigator [INVESTIGATOR_263718].
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the virtual principal investigator/call center must permit 
access to such reports.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 52
Approved, Date: 23 February 2021STUDY AND SITE CLOSURE
Study Termination
The sponsor reserves the right to terminate the study at any time for any reason at the sole 
discretion of the sponsor.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 53
Approved, Date: 23 February 202110.3 Appendix 3: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Appendix 3 provides a representative example of the scale questions that will be used in this study.

JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 54
Approved, Date: 23 February 2021

JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 55
Approved, Date: 23 February 2021

JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 56
Approved, Date: 23 February 2021

JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 57
Approved, Date: 23 February 202110.4 Appendix 4: Patient Global Impression of Change (PGIC)
Appendix 4 provides a representative example of the scale questions that will be used in this study.
Since the start of the treatment you’ve received in this study, your heart failure symptoms are: 
(select one response)
1. Very much improved
2. Somewhat improved
3. A little improved
4. No change5. A little worse
6. Somewhat worse
7. Very much worse
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 58
Approved, Date: 23 February 202110.5 Appendix 5: Patient Global Impression of Severity (PGI-S)
Appendix 5 provides a representative example of the s cale question that will be used in this study.
Considering all aspects of your heart failure symptoms right now, woul d you say your h eart failure 
symptoms are: (select one response)
1. None
2. Mild
3. Moderate
4. Severe
5. Very Severe
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 60
Approved, Date: 23 February 202110.7 Appendix 7: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study participant administered 
a medicinal (investigational or non-investigational) product. An adverse event does not necessarily 
have a causal relationship with the intervention. An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal fi nding), symptom, or disease temporally associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not related 
to that medicinal (investigational or non-investigational) product. (Definition per International 
Conference on Harmonisation [ICH]).
This includes any occurrence that is new in onset or aggravated in severity or frequency from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to All Adverse 
Events under Section 8.3.[ADDRESS_320835] adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any untoward medical occurrence that at any dose:
!results in death
!is life-threatening
(The participant was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.)
!requires inpatient hospi[INVESTIGATOR_1081]
!results in persistent or significant disability/incapacity
!is a congenital anomaly/birth defect
!is a suspected transmission of any infectious agent via a medicinal product.
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_90762]. These 
should usually be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study intervention and th e event (eg, death from anaphylaxis), the event 
must be reported as a serious and unexpected suspected adverse reaction even if it is a component 
of the study endpoint (eg, all-cause mortality).
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 61
Approved, Date: 23 February 2021Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity is not consistent with the applicable 
product reference safety information. For JNJ-28431754 (canagliflozin), the expectedness of an 
adverse event will be determined by [CONTACT_70471].
ATTRIBUTION DEFINITIONS
Assessment of Causality
The causal relationship to study treatment is determined by [CONTACT_263739] (GMS). 
The following selection should be used to assess all adverse events (AE).
Related
There is a reasonable causal relationship between study treatment administration and the AE.
Not Related
There is not a reasonable causal relationship between study treatment administration and the AE.
The term "reasonable causal relationship" means there is evidence to support a causal relationship.
SEVERITY CRITERIA
An assessment of severity grade will be made using the following general categorical descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with everyday activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity.
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal everyday activities.
SPECIAL REPORTING SITUATIONS
Safety events of interest on a sponsor study interve ntion in an interventional study that may require 
expedited reporting or safety evaluation include, but are not limited to:
!overdose of a sponsor study intervention
!suspected abuse/misuse of a sponsor study intervention
!accidental or occupational exposure to a sponsor study intervention
!any failure of expected pharmacologic action (ie, lack of effect) of a sponsor study 
intervention
!unexpected therapeutic or clinical benefit from use of a sponsor study intervention
!medication error, intercepted medication error, or potential medication error involving a 
[COMPANY_012] medicinal product (with or without patient exposure to the Johnson & 
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 62
Approved, Date: [ADDRESS_320836] label confusion, intercepted 
prescribing or dispensing errors)
!exposure to a sponsor study intervention from breastfeeding.
Special reporting situations should be reported. Any special reporting situation that meets the 
criteria of a serious adverse event should also be reported.
PROCEDURES
All Adverse Events
Adverse events, regardless of seriousness, severity, or presumed relationship to study intervention, 
must be recorded using medical terminology on the solicited AE form. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology (eg, cough, 
runny nose, sneezing, sore throat, and head congestion should be reported as "upper respi[INVESTIGATOR_42977]").
For all studies with an outpatient phase, including open-label studies, the participant must be 
provided with a "wallet (study) card" and instructed to carry this card with them for the duration 
of the study indicating the following:
!study number
!statement, in the local language(s), that the participant is participating in a clinical study
!call center name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
!site number
!participant number
!any other information that is required to do an emergency breaking of the blind.
Serious Adverse Events
All serious adverse events that have not resolved by [CONTACT_2054], or that have not resolved 
upon discontinuation of the participant's participation in the study, must be followed until any of 
the following occurs:
!the event resolves
!the event stabilizes
!the event returns to baseline, if a baseline value/status is available
!the event can be attributed to agents other than the study intervention or to factors unrelated
to study conduct
!it becomes unlikely that any additional information can be obtained (participant or health care
practitioner refusal to provide additional information, lost to follow-up after demonstration ofdue diligence with follow-up efforts)
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 63
Approved, Date: 23 February 2021!suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the course of a participant's participation in a study must be reported as a serious adverse event, except hospi[INVESTIGATOR_23741]:
!hospi[INVESTIGATOR_23742] (eg, social reasons such 
as pending placement in long-term care facility)
!surgery or procedure planned before entry into the study (must be documented). Note: 
hospi[INVESTIGATOR_23743], and where the underlying condition for which the hospi[INVESTIGATOR_23744], will not be considered serious adverse events. Any adverse event that results in a prolongation of the originally planned hospi[INVESTIGATOR_23745] a new serious adverse event.
The cause of death of a participant in a study within [ADDRESS_320837] dose of study intervention, 
whether or not the event is expected or associated with the study intervention, is considered a 
serious adverse event.
CONTACT[CONTACT_70476] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_263784](s), which will be provided as a separate document.
PRODUCT QUALITY COMPLAINT HANDLING
A product quality complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. A PQC may have 
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of participants, 
investigators, and the sponsor, and are mandated by [CONTACT_67819]. The sponsor 
has established procedures in conformity with regulatory requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_90826].
Procedures
All initial PQCs must be reported by [CONTACT_263785] [ADDRESS_320838] report the PQC 
to the sponsor according to the serious adverse event reporting timelines (refer to Section 8.3.1 , 
Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event Information). 
A sample of the suspected product should be maintained for further investigation if requested by 
[CONTACT_456].
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 64
Approved, Date: [ADDRESS_320839] Quality
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_67820](s), which will be 
provided as a separate document.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 65
Approved, Date: 23 February 202110.8 Appendix 8: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 2 02 June 2020
Amendment 1 07 February 2020
Original Protocol 07 November 2019
Amendment 2 (02 June 2020)
Overall Rationale for the Amendment: The overall reasons for the amendment are to 1) clarify 
inclusion/exclusion criteria for recruitment centers, 2) more accurately identify patients with heart 
failure in inclusion/exclusion criteria, and 3) represent patients with heart failure in medical claims 
over time and between sites of care.
Section Number
and NameDescription of Change Brief Rationale
1.1. Synopsis (Objectives and 
Endpoints, Overall Design, 
Secondary and Exploratory 
Evaluations, Statistical
Methods);
1.3. Schedule of Activities 
(SoA);3. Objectives and Endpoints;
4.1. Overall Design;
8.1. Effectiveness Assessments;[IP_ADDRESS]. Exploratory AnalysesThe term ‘stairs’ was changed to ‘floors’. To align with the data 
obtained from the Fitbit 
device, which reports this 
metric as ‘floors’ climbed 
not ‘stairs’ climbed.
1.1. Synopsis (Adverse Event Data Collection, Adverse Event 
Evaluations);3. Objectives and EndpointsThe word ‘self-reported’ was replaced by 
‘adverse’ and ‘date of the first dose of study 
intervention’ was replaced by ‘time of informed consent’.To ensure consistency for 
adverse event (AE) 
collection and timepoints across the protocol.
1.1. Synopsis (Adverse Event 
Data Collection, Adverse Event 
Evaluations);3. Objectives and EndpointsThe word ‘adverse event’ was added with 
respect to medical claims data.To clarify that medical 
claims data include AE
data.
1.1. Synopsis (Overall Design);1.3. Schedule of Activities (SoA);
4.1. Overall Design;
4.2. Scientific Rationale for Study Design;5.1. Inclusion Criteria (Criterion #4)The upper threshold of the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) for baseline overall summary score was changed 
from <80 to ≤80.To include participants 
with KCCQ summary score of 80.
1.1. Synopsis (Overall Design);1.3. Schedule of Activities 
(SoA);
4.1. Overall Design;4.2. Scientific Rationale for 
Study Design;The lower threshold (<40) of the KCCQ for 
baseline overall summary score was removed.To ensure that a larger 
number of participants 
have an opportunity to 
experience measurable health status benefit from 
treatment as there is no a 
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 66
Approved, Date: 23 February 2021Section Number
and NameDescription of Change Brief Rationale
5.1. Inclusion Criteria 
(Criterion #4)priori reason to presume 
that more symptomatic 
participants can’t benefit 
from treatment.4.2. Scientific Rationale for 
Study DesignThe participant eligibility was extended to 
include those with [LOCATION_001] Heart Association 
(NYHA) Class IV.
1.1. Synopsis (Overall Design);4.1. Overall Design‘Dates of deaths’ was added to the list of study 
assessments.To correlate with the 
exploratory endpoint ‘time 
to death’ and also for 
consistency.
1.1. Synopsis (Secondary and Exploratory Evaluations, 
Statistical Methods);
[IP_ADDRESS]. Exploratory AnalysesThe ‘time to death’ evaluation was added to the 
list of secondary and exploratory evaluations.To maintain consistency 
across the protocol. The 
term was omitted by 
[CONTACT_263786].
1.1. Synopsis (Intervention 
Groups and Duration);
4.1. Overall DesignThe term ‘claims’ was deleted from collection of 
data during the no treatment period.To explain the wider scope 
of data collection during 
the no treatment period 
(not just claims data).
1.1. Synopsis (Adverse Event Analyses);8.3. Adverse Events and 
Serious Adverse Events and 
Special Situations;9.4.3. Adverse Events AnalysisThe term ‘self-reported’ was added. To clarify AE analysis 
process
1.2. Schema The study schema was updated. To align with the changes 
in the study design and 
Schedule of Activities.
1.3. Schedule of Activities 
(SoA)Kept Screening and Baseline in separate 
columns.To clarify that Screening 
and Baseline are [ADDRESS_320840] 
periods in this study.
1.3. Schedule of Activities 
(SoA);
4.2. Scientific Rationale for 
Study Design;
5. Study PopulationScreening window was increased from [ADDRESS_320841] (EHR) 
reviews, app set-up and coordination of 
consenting, participants 
discussing with their 
physicians, families, etc and to keep the 7-day baseline period and specify the baseline activities.4.2. Scientific Rationale for Study Design (Length of Study 
Periods)Provided clarity on requirement of baseline 
period of 7 days. The text was modified as: The 
screening period of 3 weeks 28 days allows for 
an appropriate length of time for screening 
procedures to determine study eligibility (with 
EHR reviews, app set-up, completion of the 
KCCQ, and consenting). The baseline period of 7 days begins upon randomization and 
allows for shipment of the study drug and 
Fitbit device to the participant .
2. Introduction;
4.2.1. Study-Specific Ethical 
Design ConsiderationsInformation on Food and Drug Administration
approval of dapagliflozin was added.To explain the 
dapagliflozin information 
and to illustrate the benefit 
of including participants 
with heart failure with preserved ejection fraction 
(HFpEF) in this study.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 67
Approved, Date: 23 February 2021Section Number
and NameDescription of Change Brief Rationale
2.2. Benefit/Risk Assessment The text ‘or for use in patients with HFpEF ’ 
was added.To indicate that there may 
be a benefit in HFpEF 
participants where 
dapagliflozin doesn’t have 
an indication.
4.1. Overall Design Specified that inclusion/exclusion criteria, 
healthcare resource utilization, and relevant concomitant medications will be included in the claims data monitoring.To maintain consistency 
with the other sections of the protocol.
4.2. Scientific Rationale for 
Study Design;Information of KCCQ was updated. To update that KCCQ was 
recently qualified by 
[CONTACT_263787] a patient reported 
outcome instrument for 
use in clinical trials in 
heart failure.
4.2. Scientific Rationale for 
Study Design;
8.1.2. Actigraphy 
MeasurementsAdded description on actigraphy measurements. To add the description on 
Fitbit data collection that 
was missed in the previous 
protocol version.
4.4. End of Study Definition The following text was modified as: A 
participant will be considered to have ended
completed the treatment period of the study (at 
3 months), regardless of whether the participant 
has completed is on the study intervention, if he 
or she has completed assessments at Month [ADDRESS_320842] completed the study intervention.
4.4. End of Study Definition The term ‘clinical research organization’ was 
added.To clarify that the study 
partner prefers to a clinical research organization 
partner and not participant.
5.1. Inclusion Criteria;
5.2. Exclusion Criteria;
5.2. Exclusion Criteria (Criteria 
#1, 3, 5, 6, and 7)Clarified that each potential participant was
required to satisfy the inclusion/exclusion 
criteria ‘prior to enrollment (consent date)’.
The extra term ‘prior to enrollment ’ was deleted from exclusion criteria 1, 3, and 5.The extra term ‘of the screening visit’ was deleted from exclusion criterion 6.
The extra term ‘of consent’ was deleted from 
exclusion criterion 7.To clarify the timing for 
fulfillment of 
inclusion/exclusion 
criteria.
5.1. Inclusion Criteria (Criterion #3)Definitions of heart failure with reduced ejection 
fraction (HFrEF) and HFpEF were updated. 
Added spi[INVESTIGATOR_263719].To clarify and align with 
the information received 
from site principal 
investigators and Steering Committee on definitions 
of HFrEF and HFpEF for 
this virtual study and diagnosis confirmation 
within 18 months instead 
of 1 year.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 68
Approved, Date: 23 February 2021Section Number
and NameDescription of Change Brief Rationale
5.2. Exclusion Criteria 
(Criterion #4)The text ‘from the most recent assessment’ was 
added.To clarify the timing of 
assessment of stage 4 or 5 
chronic kidney disease for 
exclusion of participants from the study.
5.2. Exclusion Criteria (Criterion #8)The text ‘any condition for which, in the opi[INVESTIGATOR_8574], participation would not be in the best interest of the participant (eg, compromise the well-being) or that could 
prevent, limit, or confound the protocol-
specified assessments’ was added.To explicitly describe the 
exclusion of participants with compromised well-being or whose 
participation could 
prevent, limit, or confound 
the protocol-specified assessments.
5.2. Exclusion Criteria 
(Criterion #12)The text ‘receiving an investigational study 
medication’ was added.To clarify that participants 
with ongoing treatment 
with an investigational 
agent should be excluded 
from the study, but those 
in studies without an 
investigational agent are eligible to participate.
5.2. Exclusion Criteria 
(Criterion #13)A new exclusion criterion #13 was added:
‘has a left ventricular assist device’.To exclude the factors that 
can alter the health status 
and would confound the 
ability to define a benefit 
from treatment with the study drug.
5.2. Exclusion Criteria (Criterion #14)A new exclusion criterion # 14 was added:
‘patient identity or association with enrolling 
network cannot be verified’.To exclude those 
participants whose identity 
cannot be verified.
5.4. Screen Failures Updated the criteria for rescreening of 
participants.To allow and outline for 
the rescreening of 
participants.
5.4. Screen Failures The following text was modified as: All 
potential participants who electronically sign the 
remote e consent opt in to participate in the 
study on the website will receive a unique 
identifier in the study database held by a third-
party representative.To emphasize that the 
participants will receive a 
unique study number when 
they opt in to participate in 
the study which is prior to 
enrollment (signing of consent).
6.3. Measures to Minimize Bias: Randomization and BlindingThe following text was modified as: The IxR 
will provide the kit number of the study 
intervention bottle(s) to be dispensed for each 
randomly assigned participant to begin dosing
on Day 1 of the double-
blind treatment period.To indicate that the kit 
numbers are not assigned 
on Day 1 but that study 
intervention dosing should 
begin on Day 1.
6.4. Study Intervention 
ComplianceRe-education of the participant on importance of 
dairy completion was added.To indicate that diary 
should be completed to 
track the study intervention compliance data.
7.2. Participant 
Discontinuation/Withdrawal 
from the StudyThe following text was modified as: If 
applicable, the participant is lost to follow-up , 
vital status will still be attempted to be 
obtained for collection at study end through the 
participant’s physician, medical claims, or To specify that vital status 
should be obtained, if 
possible, in case 
participant is lost to follow-up.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 69
Approved, Date: 23 February 2021Section Number
and NameDescription of Change Brief Rationale
public information according to local guidelines 
and as allowed by [CONTACT_427]
7.2. Participant 
Discontinuation/Withdrawal 
from the StudyThe information on home and work contact 
[CONTACT_263788].To indicate that the app 
can only store smartphone 
contact [CONTACT_6227].
7.2. Participant Discontinuation/Withdrawal 
from the StudyThe following text was added: Follow-up can 
also be done with the help of the study site 
personnel.To specify that besides the 
call center, study site can
also help with follow-up.
8. Study Assessments and 
Procedures (Overview)The following text was deleted: Health Resource 
Utilization (HRU) and health economics data 
will be collected. Refer to Section 8.2.4, 
Healthcare Resource Utilization and Health 
Economics for details.To remove duplicate 
information.
8.2.4. Healthcare resource Utilization and Health EconomicsAdded ‘discharge destination’ information to the 
list of healthcare resource utilization and health economics dataTo maintain consistency 
with text in the other sections of the protocol.
8.3. Adverse Events and Serious Adverse Events and 
Special SituationsThe text was modified to indicate that the 
principal investigator [INVESTIGATOR_263720].To update how the 
principal investigator [INVESTIGATOR_263721]’s 
treating physician based on the confirmed process.
8.3. Adverse Events and 
Serious Adverse Events and 
Special Situations;9.4.3. Adverse Events AnalysisEmergency department visits was added as a 
criteria for aggregation of AEs collection from 
claims.To be consistent by 
[CONTACT_263789].
8.3.1. Time Period and 
Frequency for Collecting 
Adverse Event and Serious Adverse Event InformationThe following text was modified as: All 
participant reported adverse events suspected to 
be related to the study intervention, whether 
serious or non-serious, will be collected from the time a signed and dated ICF is obtained until the
participant completes their participation in the 3-
month treatment period plus 30 days.To clarify that all AEs (not 
just those suspected to be 
related to study intervention) should be 
collected.
8.3.4. Adverse Events of 
InterestAdditional adverse events of interest were 
specified.To expand the scope of 
AEs of interest to be 
collected in the study.
9.3. Populations for Analyses 
(Table 2)Updated the definition of ‘per protocol’ 
population.To clarify the definition of 
per protocol population.
10.2. Appendix 2: Regulatory, 
Ethical, and Study Oversight 
Considerations (Regulatory and 
Ethical Considerations [Protocol Amendments])The following text was deleted: The data 
recorded in the source documents will reflect 
any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.To remove non-applicable 
data source in this virtual 
study.
10.2. Appendix 2: Regulatory, 
Ethical, and Study Oversight 
Considerations (Regulatory and 
Ethical Considerations 
[Protocol Amendments])Specified that the departure from the protocol 
information will be recorded by [CONTACT_456].To provide clarity on who 
will record the departure 
from protocol information.
10.6. Appendix 6: Participant 
Satisfaction SurveyAdded numeric grading of 1 to 5. To provide the scoring 
used on the participant 
satisfaction survey which was omitted in previous 
versions.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 70
Approved, Date: 23 February 2021Section Number
and NameDescription of Change Brief Rationale
10.7. Appendix 7: Adverse 
Events: Definitions and 
Procedures for Recording, 
Evaluating, Follow-up, and 
Reporting (Product Quality 
Complaint Handling)Modified the text to indicate that instead of 
study site personnel, the call center will report 
the product quality complaint to the sponsor in 
case a product defect is combined with serious 
AE.To provide clarity and for 
consistency across the 
study.
References New references (#1, 3, 14) were added. Other 
reference numbers cited within the protocol were updated.References added to 
support the study.
6.1. Study Interventions 
AdministeredAssigned table number to ‘Description of Study 
Interventions’ table. Table numbering of other 
tables were updated.Minor errors were noted.
8.3.3. Pregnancy The following text was modified as ‘Any 
participant who becomes pregnant during the study must be promptly withdrawn
discontinued from the study and discontinue 
further study intervention’.
Throughout the protocol Minor grammatical, formatting, or consistency 
changes were made.
Amendment 1 (07 February 2020)
Overall Rationale for the Amendment: The overall reason for the amendment is to remove 
Return of Results (RoR) to align with Janssen standard operating procedure (SOP), update the 
study overview schema to align with the protocol, and to define that the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) overall summary score will be used for the baseline 
assessment.
Section Number
and NameDescription of Change Brief Rationale
Synopsis Overall Design; 1.3 
Schedule of activities (SoA); 
4.1. Overall Design; 4.2. 
Scientific Rationale for Study Design; 5.1. Inclusion Criteria; 8.1.1. KCCQ ScoresClarified that KCCQ overall summary score will 
be evaluated at Screening/Baseline to determine 
participant eligibility and other KCCQ domains 
and summary scores will be calculated at baseline and subsequent postbaseline timepoints, respectively.To clarify that KCCQ 
baseline overall summary 
score will be used to 
determine participant eligibility at screening/baseline.
Synopsis Objectives and Endpoints; Synopsis 
Intervention Groups and 
Duration; 3. Objectives and 
Endpoints; 4.1 Overall DesignThe term of “Return of Results (RoR)” was 
removed and term “Participant Unblinding” was added.
Text related to RoR including exploratory 
objective and endpoint was deleted.Janssen SOP does not 
allow for “RoR” to participants for an 
approved drug.
1.2 Schema Schematic Overview of the Study was replaced 
with an updated figure (1).To align with protocol.
1.3 Schedule of activities (SoA) SoA was updated to clarify study day for date of 
first dose and other timepoints. Also, footnote
“d” related to claims data collection and 
reporting of adverse events were updated.To specify the timepoints 
(in days) for clarity and 
added a baseline period of 
up to [ADDRESS_320843] number is not 
applicable for the current study.
6.3 Measures to Minimize Bias: Randomization and BlindingInformation related to blind breaking was 
updated. Clarified that “Study Responsible 
Physician “or “other sponsor physician” designee may in an emergency determine the To update appropriate 
process for study
unblinding.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 71
Approved, Date: 23 February 2021Section Number
and NameDescription of Change Brief Rationale
identity of the study intervention by [CONTACT_263790].
9.4.3 Adverse event analysis Clarified that adverse events reported from call 
center will be reported separately from those 
obtained from claims data.To clarify the adverse 
event reporting
10.7 Appendix 7: Adverse 
Events: Definitions and 
Procedures for Recording, 
Evaluating, Follow-up, and ReportingClarified that the causal relationship to the study 
treatment is determined by [CONTACT_263791].
Text related to responsibility of virtual principal investigator [INVESTIGATOR_263722].To align with the protocol 
and the design of the study 
and to remove incorrect 
text.Clarified the responsibility 
of virtual principal 
investigator.
Throughout the protocol Minor grammatical, formatting, or spelling 
changes were made.Minor errors were noted.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 72
Approved, Date: 23 February 202111. REFERENCES
1. Bertram Pi[INVESTIGATOR_32887], Pfeffer MA, Assmann SF, et al.  Spi[INVESTIGATOR_263723]. N Engl J Med. 2014;370:1383-1392.
2. Butler J (2017), Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure 
with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017;19(11):1390-1400.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA 
Guideline for the Management of Heart Failure. JACC. 2017;70(6):776-803.
4. DDT COA #000084: Kansas City Cardiomyopathy Questionnaire (KCCQ). https://www fda.gov/drugs/ddt-
coa-000084-kansas-city-cardiomyopathy-questionnaire-kccq.
5. Dreyer RP (2016), Jones PG, Kutty S, Spertus JA. Quantifying clinical change: discrepancies between patients' 
and providers' perspectives. Qual Life Res. 2016 Sep;25(9):2213-2220.
6. European Medicines Agency (EMEA) (2012). Guidelin e on clinical investigation of medicinal products in the 
treatment or prevention of diabetes mellitus. 14 May 2012; CPMP/EWP/1080/00 Rev. 1. Committee for 
Medicinal Products for Human Use (CHMP).
7. Food and Drug Administration (FDA) (2008). Guidance for industry: Diabetes Mellitus: Developi[INVESTIGATOR_263724]. U.S. Department of Health and Human Services, Food and 
Drug Administration, Center for Drug Evaluation and Research (CDER), February 2008, Clinical/Medical.
8. Food and Drug Administration (F DA) (2019). Treatment for heart failure: Endpoints for drug development, 
Guidance for Industry. Draft guidance un 2019; US Department of Health and Human Service, Food and Drug 
Administration.
9. Gail M (1985), Simon R. Testing for qualitative interactions between treatment effects and patient subsets. 
Biometrics. 1985 Jun;41(2):361-372.
10. Green CP (2000), Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City 
Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 
2000;35:1245-1255.
11. Investigator's Brochure: JNJ-28431754 (Canagliflozin) Edition 15. Janssen Research and Development, LLC 
(9 Nov 2017).
12. Joseph SM (2013), Novak E, Arnold SV, et al. Comparable performance of the Kansas City Cardiomyopathy 
Questionnaire in patients with heart failure with preserved and reduced ejection fraction Circ Heart Fail. 2013 
Nov;6(6):1139-1146.
13. Kelkar AA (2016), Spertus J, Pang P, et al. Utility of patient-reported outcome instruments in heart failure.
JACC Heart Failure 2016;4(3):165-175.
14. Mahaffey KW (2019), Jardine MJ, Bompoint S, et al. Canag liflozin and cardiovascular and renal outcomes in 
type 2 diabetes and chronic kidney disease in primary and secondary cardiovascular prevention groups: results 
from the randomized CREDENCE trial. Circulation. 2019 Aug 27;140(9):739-750.
15. Mahaffey KW (2018), Neal B, Perkovic B, et al. Canagliflozin for primary and secondary prevention of 
cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018 Jan 23;137(4):323-334.
16. McMurray JJV (2019), Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. 
Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Sep 19.
17. Medical Device Development Tools Program (2016). Medical Development Tool Qualification Decision 
Summary for Kansas City Cardiomyopathy Questionnaire (KCCQ). Available from: 
https://www.fda.gov/downloads/MedicalDevices/ScienceandResearch/MedicalDeviceDevelopmentToolsMDDT/UCM581761.pdf. Accessed on 13 November 2017.
18. Monami M (2014), Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-
analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689-697.
JNJ-28431754 (canagliflozin) (INVOKANA)
Clinical Protocol 28431754HFA3002 Amendment 3
CONFIDENTIAL – FOIA Exemptions Apply in U.S. 73
Approved, Date: 23 February 202119. Mosenzon O ( 2019), Wiviott SD, Cahn A, et. al. Effects of dapagliflozin on development and progression of 
kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. 
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617.
20. Nassif ME (2019), Kosiborod M. Effects of sodium-sodglucose cotransporter type 2 inhibitors in heart failure. 
Diabetes Obes Metab. 2019;21(Suppl. 2):19-23.
21. Nassif ME (2019), Windsor SL, Tang F, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional 
Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 
[ADDRESS_320844] 29;140(18):1463-1476.
22. National Kidney Foundation (2012). KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. 
Am J Kidney DIS. 2012;60(5):850-886.
23. Nichols GA (2001), Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, 
incidence, and risk factors. Diabetes Care. 2001;24(9):1614-1619.
24. Nichols GA (2004), Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure 
in type 2 diabetes. Diabetes Care. 2004;27(8):1879-1884.
25. Packer M (2017), Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 
inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025-1029.
26. Radholm K (2018), Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. 
Results From the CANVAS Program. Circ. 2018;138:458-468.
27. Ryan PB (2018), Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors 
and non-SGLT2 inhibitors on the risk of hospi[INVESTIGATOR_263725] 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes 
Metab. 2018;20(11):2585-2597.
28. Sezai A (2019), Sekino H, Unosawa S, et al. Canagliflozin for Japanese patients with chronic heart failure and 
type II diabetes. Cardiovasc Diabetol. (2019) Jun 5;18(1):76.
29. Spertus J (2005), Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a 
comparison of methods. Am Heart J 2005;150(4):707-715.
30. Zinman B (2015), Wanner C, Lachin JM, et. al. Empagliflozin, cardiovascular outcomes and mortality in type 
2 diabetes. N Engl J Med 2015;373:2117-2128.
ÞÙ$c+*®Hb+ƌ[ƌ ;;ğANĝƉ]ƌ[ØmIà]ƌ
eAN;İƌæŗ SAƌ$c+*ƌĮƌ Hb+Í :*GG$ƌ Ķ>Ď>Tƌ*ƌ
	



Ý-Úµd¼·¯Á¿½ƌ\ňĠ'ĪĲĳƊ4ƌ\×mkß-,ƌ
f'}ķčĀOƌ ç6ŊOƌ9da¸°ÂÀaÎÌ,»``9ƌ ,B ƌ¹ƌ


	

±ƌ&ƌ6%ƌVMƌ
!ƌ(ƌ%/!ƌ VMƌƌāƌ ƌĸŜFƌ ƌĞƌtŇƆ4/ƌ#ƌ VMƌXƁ©ƌ²ƌƌ
3WEƌ 	ƌWƂƌŤƌ #	ƌ 0	ŠĦƌpƌƌJ1Œƌ&uƌ#ƌ żƌ&?ƌŮďƌ ?ġpť?)ƌ
Ïƌƌ
ŷ	ƌ J
	ƌLƌ ƌ
!Jƌ rƌƌ
P	ƌ3wŏC1ƌƌ ƌŸůƌDK 
s?ƌƌ1Kƌ Ž0ƌ
ćƌƌ &	ƌ#Eƌėƌ 0ƌŶZ)ƌŘƌž'ƌ tŰƌ&ƌ 1%	!ƌ ƌ0	1ƌƌ 	4ű!uƌzƌ0FƌƌęŴƃƌ4wŐĹĺĊƌ
Q/C4/ƌ&ƌ XƄƌ(CP"ħ3ƌƌ XƌLƌ ĤƌSWFƌƌŦƌs{/3ƌ ŋLƌĚī3ĬSƇ )ƌ


" 
	" !"
"
-%2ƌ
řƌ	
įĻŢũ|ŭŲŧ|Ōļƌ 
	
ãă2
ƌóŬƈŔqƌ6œņšĔqŚƌ èô éõĽƌ þöno ÷øùúnoƌ ûƌ
ÔB7~ųE} Äƌ Û<ń87Đ(ƌl(ĜċƌÉĂ!8ƌ   	 	
 
lĢBąUŵśĕÅƌ_¡¢_
ƋòüêÊ
.....ýƌ£¤¥¦ g%"
Æ
ŪĨÜÿƅƌâōľĴƌ ñĖĄŝƌ
"Óvƌūģ
ƌ< DK77ƌQƌ '
x ƌ Y2ĈRƌvƌyƌŅ8@ Cƌx @đƌY6B@ƌ"yƌYRĒƌĘƌ "zƌ#ƌQ ē ƌ
ŁŎUěĭČ<"~Ŀƌı'ƌ=
ƌ
! ƌ=ƌĥ
ƌŻ
7{@"ƌƌ U	ƌ8ŕ(8D^ƌ Pƌ%ƌ
"Oƌ Ć
ŀ2
 Eƌ 	
ŉŨƌ=	ƌD	Ŗ#6	)ƌ
fk-jÐgh-íÑ,áƌ §hſ2
 łţƌÈ

'Zƌ(ƌïªë)ƌ
,

ŞőŹ^ƌ 
¶ºƌj=R#rşZƌ9­9³ƌ
eIä:ÖiåîÕƌ¨ :IÒƌiƀ >5TNƌ 55AFƌĩŃƌ ð«ì¬ƌ
55ź
ƌË< T
Çƌ$*ƌ:>ĉĵ;ƌ$G$´ƌÃ¾ƌ
H+ƌ